癯

International Journal for Parasitology: Drugs and Drug Resistance 7 (2017) 51-60



Contents lists available at ScienceDirect

International Journal for Parasitology: Drugs and Drug Resistance

journal homepage: www.elsevier.com/locate/ijpddr

Insecticidal activities of histone deacetylase inhibitors against a dipteran parasite of sheep, *Lucilia cuprina*



CrossMark

Neil H. Bagnall ^{a, 1}, Barney M. Hines ^{a, 1}, Andrew J. Lucke ^b, Praveer K. Gupta ^b, Robert C. Reid ^b, David P. Fairlie ^b, Andrew C. Kotze ^{a, *}

^a CSIRO Agriculture and Food, St. Lucia, Queensland 4067, Australia

^b Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia

ARTICLE INFO

Article history: Received 2 November 2016 Received in revised form 6 January 2017 Accepted 9 January 2017 Available online 10 January 2017

Keywords: Lucilia cuprina Histone deacetylase Insecticide Control

ABSTRACT

Histone deacetylase inhibitors (HDACi) are being investigated for the control of various human parasites. Here we investigate their potential as insecticides for the control of a major ecto-parasite of sheep, the Australian sheep blowfly, Lucilia cuprina. We assessed the ability of HDACi from various chemical classes to inhibit the development of blowfly larvae in vitro, and to inhibit HDAC activity in nuclear protein extracts prepared from blowfly eggs. The HDACi prodrug romidepsin, a cyclic depsipeptide that forms a thiolate, was the most potent inhibitor of larval growth, with equivalent or greater potency than three commercial blowfly insecticides. Other HDACi with potent activity were hydroxamic acids (trichostatin, CUDC-907, AR-42), a thioester (KD5170), a disulphide (Psammaplin A), and a cyclic tetrapeptide bearing a ketone (apicidin). On the other hand, no insecticidal activity was observed for certain other hydroxamic acids, fatty acids, and the sesquiterpene lactone parthenolide. The structural diversity of the 31 hydroxamic acids examined here revealed some structural requirements for insecticidal activity; for example, among compounds with flexible linear zinc-binding extensions, greater potency was observed in the presence of branched capping groups that likely make multiple interactions with the blowfly HDAC enzymes. The insecticidal activity correlated with inhibition of HDAC activity in blowfly nuclear protein extracts, indicating that the toxicity was most likely due to inhibition of HDAC enzymes in the blowfly larvae. The inhibitor potencies against blowfly larvae are different from inhibition of human HDACs, suggesting some selectivity for human over blowfly HDACs, and a potential for developing compounds with the inverse selectivity. In summary, these novel findings support blowfly HDAC enzymes as new targets for blowfly control, and point to development of HDAC inhibitors as a promising new class of insecticides.

© 2017 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

The Australian sheep blowfly (*Lucilia cuprina*) is an important ecto-parasite that causes fly strike, which has significant health and welfare, as well as economic, impacts on the sheep industry in Australia (Sandeman et al., 2014). The female blowfly is attracted to the sheep by odours, particularly those associated with bacterial infections in damp fleece, and lays eggs (Tellam and Bowles, 1997). The developing larvae feed on the sheep, causing severe tissue

¹ These authors contributed equally to the study.

damage, toxaemia, and in some cases, death. The consequent loss of livestock, costs of preventative and curative chemical treatments, and animal welfare issues place significant economic burdens on livestock enterprises (Lane et al., 2015). The blowfly has developed resistance to various classes of chemical insecticides used for its control, including organochlorines, organophosphates, the benzoyl-phenyl urea diflubenzuron (Levot, 1995; Sandeman et al., 2014) as well as the triazine cyromazine (Levot, 2012). Only two preventative blowfly control chemicals, the macrocyclic lactone ivermectin and the cyanopyrimidine dicyclanil, remain effective with no resistance yet reported. There is therefore a need to identify new chemical classes of insecticides, preferably with different target proteins, to control this important parasitic insect.

Histone deacetylase inhibitors (HDACi) have been recognised as therapeutic targets in cancer for many years (Cairns, 2001), with a

http://dx.doi.org/10.1016/j.ijpddr.2017.01.001

2211-3207/© 2017 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).

^{*} Corresponding author. CSIRO Agriculture and Food, 306 Carmody Rd., St. Lucia, Queensland 4067, Australia.

E-mail address: Andrew.kotze@csiro.au (A.C. Kotze).

number in clinical use or clinical trials as anti-cancer drugs. They have also been studied extensively over recent years for their potential in chemotherapy for parasitic diseases of humans, including malaria, toxoplasmosis, trypanosomiasis, schistosomiasis and leishamaniasis (Andrews et al., 2012a,b; Marek et al., 2015). HDAC enzymes have been studied extensively in the model dipteran insect Drosophila with respect to their roles in longevity and memory formation (Fitzsimons et al., 2013: Proshkina et al., 2015: Schwartz et al., 2016), with a Drosophila model providing experimental evidence to highlight HDACi as potential therapeutics for the treatment of Huntington's disease (Sharma and Taliyan, 2015). However, only a single study has reported the insecticidal activity of an HDACi against this fly species, with Pile et al. (2001) noting that trichostatin caused lethality during larval development. The potential for HDACi as insecticides was recently highlighted by Kotze et al. (2015) who showed that trichostatin and suberoylanilide hydroxamic acid (SAHA) were able to inhibit the development of sheep blowfly larvae in vitro. That report also highlighted similarities and differences in amino acid sequences of blowfly and human HDAC enzymes, with differences particularly noted between species for the Class II enzymes HDAC4 and 6, and the Class IV HDAC11, raising the possibility of identifying insect-specific inhibitors.

The present study expands on our earlier report of insecticidal activity for trichostatin and SAHA (Kotze et al., 2015) by examining other HDACi with different chemical structures and mechanisms of action. We focus on hydroxamic acids since these are the best known group of HDACi, but also include inhibitors with different chemical components, such as benzamides, thioesters, thiolates, disufides, cyclic depsi- and tetra-peptides, fatty acids, and sesquiterpene lactones (Table 1). We measure the effects of these HDACi on the development of blowfly larvae (larval growth rate and pupation rate) and on the HDAC enzyme activity of nuclear protein extracts prepared from blowfly eggs. We also compare these results with reported inhibitory activities against human HDAC enzymes as an initial step towards identification of insect-specific inhibitors.

2. Materials and methods

2.1. Insects and chemicals

The L. cuprina used in this study were from the laboratory reference drug-susceptible LS strain, derived from collections made in the Australian Capital Territory (Canberra, Australia) over 40 years ago. This strain has been maintained in a laboratory since that time (in Canberra for 30 years, and then at CSIRO and University of Queensland laboratories in Brisbane for the last 10 years), and has no history of exposure to insecticides. Adult flies were maintained at 28 °C and 80% relative humidity with a daily photoperiod of light 16 h and dark 8 h. Adults were fed a diet of sugar and water, while larvae were raised on a wheatgerm culture medium (Tachibana and Numata, 2001). Protein meals (bovine liver) were provided on days 4 and 8 after adult eclosion in order to prime adult flies for subsequent egg-laying. For provision of eggs for bioassays, liver was placed into cages of gravid flies for a period of two hours (12 p.m. until 2 p.m.). The liver was then removed and kept at room temperature overnight. At 10 a.m. the next morning, assays were established using the newly-hatched larvae.

HDACi were synthesized by reported procedures or obtained from commercial sources (Table 1). The structures are shown in Supplementary Figs. 1–4. Stock solutions for use in larval bioassays were prepared in ethanol at a concentration of 1 mg/mL. In cases where the compound did not dissolve at this concentration the solutions were further diluted 2-fold with ethanol until no precipitate was evident (to give stocks at 0.5 or 0.25 mg/mL). Exceptions were CUDC-907 and MC1568 which required dilution to a concentration of 0.05 mg/mL. The commercial insecticide stocks used as controls were prepared at 1 mg/mL in water (cyromazine and dicyclanil) or acetone (diflubenzuron). Stock solutions of HDACi for use in nuclear extract HDAC enzyme assays were prepared at 1 mg/mL in DMSO.

2.2. Blowfly larval bioassay

The effects of HDACi on the growth of blowfly larvae was assessed using a bioassay system in which larvae were allowed to develop on cotton wool impregnated with the compounds at various concentrations (modified slightly from Kotze et al., 2014). Briefly, 4 mL aliquots of HDACi or commercial insecticide solutions were added to cotton wool plugs and the solvent (4 mL of either ethanol, acetone, or water) was allowed to evaporate overnight. Control containers were prepared by addition of 4 mL of the relevant solvent to the cotton wool. The next day (Day 0 of the assay), a sheep serum-based medium (80 g/L yeast extract (Merck), 1.6 mg/ mL tylosin (Sigma) in lamb serum (Life Technologies) buffered with 35 mM KH₂PO₄, pH7.5) was added to the cotton wool, and groups of 50 freshly-hatched larvae (prepared as described in section 2.1, above) were placed onto the cotton wool. The assay pots were placed at 28 °C. In order to calculate mean larval weight at the beginning of the drug exposure period, two groups of 100 larvae were collected, blotted dry on paper towel, weighed and discarded on Day 0. After 24 h (Day 1), 3 larvae were removed from each container, weighed, and discarded. The remaining larvae were fed with 1 mL of nutrient medium on Day 1, and then 2 mL on each of Davs 2 and 3. Late on Dav 4. the containers were placed into larger pots with a layer of sand at the base to serve as a medium for pupation, and returned to the incubator. Pupae were recovered from the sand on sieves on Day 9, and counted.

Each compound was examined at four or five serially diluted (5fold) concentrations. Each experiment consisted of a single container at each concentration of HDAC inhibitor or insecticide, alongside 4 control assays. Two separate experiments were performed for each compound. The effect of the compounds on larval development was defined in two ways:

- i) Larval weight gain in first 24 h; the total weight gain of the 3 larvae sampled on Day 1 was expressed as a percentage of the mean of the weight gain of the 3 larvae sampled from each of the 4 control containers (weight gain was calculated by difference using weight on Day 1 and the mean weight of larvae on Day 0);
- ii) Pupation rate; the number of pupae in each drug-treated container was expressed as a percentage of the mean number of pupae in the 4 control containers.

The larval weight and pupation rate dose-response data were analysed with GraphPad Prism[®] software using non-linear regression, with the 'variable slope' option selected, in order to calculate IC_{50} values (with 95% Confidence Intervals) representing the concentration of inhibitor required to reduce the larval weight gain or pupation rate to 50% of that measured in control (no drug) treatments.

2.3. Nuclear extract preparation

Nuclear extracts were prepared from blowfly eggs (0.5 g) using a Nuclear Extraction kit (Millipore, USA) following the manufacturer's protocol with some modifications. The chorion was removed by soaking for 80 s in a solution of bleach (2% v/v), followed by centrifugation to sediment the eggs. The eggs were washed 3 times in ice cold PBS. Complete Mini Protease Inhibitor (Roche, Basel

Table	1			
HDAC	inhibitors	and	insecticides	used.

Dybox Class I and II. Yoshida et al., 1995 Selleckchem Hydroxamic add CUDC-907 Class I and II. Yoshida et al., 1995 Selleckchem AR-42 Class I and II. Class I and II. Kahaberg et al., 2006 synthesized Quisinostat Class I and II. Art et al., 2005 Aperatio Aperatio PCSD First Stand II. Art et al., 2007 Aperation Appendix PCSD First Stand II. Art et al., 2007 Appendix Appendix PCSD First Stand II. Appendix Appendix Appendix Pracincats (19939) Class I and II. Class I and II. Appendix Appendix SHAA Class I and II. Class I and II. Appendix Appendix Appendix SHAA Class I and II. Class I and II. Appendix Appendix Appendix SHAA Class I and II. Reservice I al., 2007 Appendix Appendix SHAA Class I and II. Reservice I al., 2008 Appendix Appendix SHAA	Drug group	Compound	Human HDACs Inhibited	References	Source
Hydroxamic acid:FridoscatinCass I and IIYoshida et al. 1995SelleckchemCUDC-907Class I and II. aloo class I PJaKQui et al. 2012SelfeckchemALT 179-3bClass I and II.Let al. 2005. Tseng et al. 2015ApexBioALT 24Class I and II.Let al. 2005. Tseng et al. 2015SelfeckchemQuisinostarClass I and II.Let al. 2012. Tseng et al. 2012ApexBioPC50IIDAC6Ergman et al. 2012.ApexBioNextursatar AHDAC6Ergman et al. 2012.ApexBioParolinostatClass I and IIApexBioApexBioParolinostatClass I and II.ApexBioApexBioSBHAClass I and II.Class I and II.ApexBioSBHAClass I and II.ApexBioApexBioSBHAClass I and II.ApexBioApexBioBalton Class I and II.Class I and II.ApexBioSBHAClass I and II.ApexBioApexBioBalton Class I and II.Class I and II.ApexBioApexBioClass I and II.ApexBioApexBio <td>1) HDAC inhihito</td> <td></td> <td></td> <td></td> <td></td>	1) HDAC inhihito				
CUDC-007. Cas I and II: alo class IPI9K Can et al., 2010 et al., 2017. elect.chem (al., 2017) elect.chem (al., 201	Hydroxamic acids	Trichostatin	Class Land II	Voshida et al. 1995	Selleckchem
All 79-3bClass I and IILabraberg et 3, 2006synthesizedQuisinostatClass I and IIArt et al. 2005; Teng et al. 2015ApeshioVS30HDAC6Clup at el al. 2012ApeshioNextursati AHDAC6Bergman et al. 2012ApeshioNextursati AHDAC6Bergman et al. 2012ApeshioNextursati AClass I and IIAtt et al. 2012ApeshioPanebinostatClass I and IIAttadia, 2009; Alleymar and Kumar, ApeshioApeshioAut 179-84Class I and IIAttadia, 2009; Alleymar and Kumar, ApeshioAppeshioSBHAClass I and IIClass I and IIAttadia, 2009; Alleymar and Kumar, ApeshioAppeshioSBHAClass I and IIClass I and IIAppeshioAppeshioSBHAClass I and IIClass I and IIAppeshioAppeshioSHA (Vorinostat)Class I and IIAppeshioAppeshioM344Class I and IIMondevect et al. 2006AppeshioBelinostatClass I and IIMondevect et al. 2001AppeshioDotatiotatClass I and IIMondevect et al. 2010AppeshioDotatiotatClass	Hydroxamic acids	CLIDC-907	Class Land II: also class L DI3K	Oian et al. 2012	Selleckchem
Ak-42Class I and IIIn rel al., 2015; Trange et al., 2015AppessionOutsino statClass I and IIArt set al., 2010AppessionPC50HDAC6Gupta et al., 2010synthesizedPC50HDAC6Gupta et al., 2010synthesizedPC50Class I and IIKathese et al., 2005synthesizedParatinostatClass I and IIKathese et al., 2005AppessionPracinostatClass I and IINorotroy-Dierrary et al., 2010AppessionPracinostatClass I and IINorotroy-Dierrary et al., 2016AppessionPracinostatClass I and IINorotroy-Dierrary et al., 2016AppessionSBHAClass I and IIKlainteeg et al., 2005AppessionSBHAClass I and IIHeatPracinostat (SB939)AppessionSBHAClass I and IIHeatPracinostat (SB939)AppessionSBHAClass I and IIHeatPracinostatAppessionSBHAClass I and IIHeatPracinostatAppessionSBHAClass I and IIKorlowski et al., 2007AppessionDraxinostatClass I and IIKorlowski et al., 2007AppessionSBHAClass I and IIKorlowski et al., 2007Sigma-AddrichDraxinostatClass I and IIKorlowski et al., 2007Sigma-AddrichDraxinostatClass I and IIKorlowski et al., 2007Sigma-AddrichNaphtohsytrowanic acidBlass I and IIKorlowski et al., 2007Sigma-AddrichDraxinostatCla		AL1179_3b	Class Land II	Kahnberg et al. 2006	synthesized
Open stateCase I and IIArts of al. 2009SelectionSelectionPCS0HDAC6Cupta et al. 2010SpelticionSpelticionNettursdar AHDAC6Dergman et al. 2012ApestioNettursdar AClass I and IIAtabibarg et al. 2006Speltinar and Komar, ApestioApestioPanobinosatClass I and IINototry Dorge Rulemar and Komar, ApestioApestioPracinosat (SB939)Class I and IINototry Dorge Rulemar and Komar, ApestioApestioSBHAClass I and IIRichon et al. 1998ApestioAL-1179-85Class I and IIRichon et al. 2003ApestioAL-1179-85Class I and IILocni et al. 2006SynthesizedRichon et al. 2016CivinosataClass I and IILocni et al. 2006ApestioGuinosataClass I and IILocni et al. 2006ApestioRisminosatClass I and IILocni et al. 2007ApestioRisminosatClass I and IIKomberg et al. 2001ApestioRisminosatClass I and IIKomberg et al. 2006ApestioRisminosatClass I and IIKomberg et al. 2006SynthesizedNaphtholytoramic addHDAC6Koralowski et al. 2000ApestioHydrosamateClass I and IIAndersex et al. 2000ApestioKorali AClass I and IIAndersex et al. 2000ApestioHydrosamateClass I and IIAndersex et al. 2000ApestioKorali AClass I and IIApestioApestioH		AR_42		Lu et al. 2005: Teeng et al. 2015	ApevBio
SectorConstructConstructSectorSectorNettorNettorEars Land IIKalnberg et al. 2005synthesizedAL179-84Class Land IIKalnberg et al. 2005synthesizedPanobinostatClass Land IIAcadja. 2009: Rajkunar and Kunar, 2016ApesBioSBHAClass Land IINovotry. Diemayer et al. 2010ApesBioSBHAClass Land IIRichore et al. 1995ApesBioSHAClass Land IIRichore et al. 1995ApesBioSHA (Vorinostat)Class Land IIRichore et al. 2005synthesizedAL179-85Class Land IIRichore et al. 2005synthesizedAM44Class Land IIRichore et al. 2010ApesBioM344Class Land IIHelweg et al. 2001ApesBioBelinostatClass Land IIRichore et al. 2010ApesBioDroxinostatClass Land IINordelPlumb et al. 2007Sigma-MatrichoreArbitohyttyraamic adClass Land IIWood et al. 2010ApesBioDroxinostatClass Land IIWood et al. 2010ApesBioDroxinostatClass Land IIWood et al. 2010ApesBioArbitohyttyraamic adClass Land IIWood et al. 2010ApesBioVMAH (Volproic acidClass Land IIKathereeBiotechWood et al. 2010SeleckchemMatriceSeleckchemNVS8HDAC Bave Land IILai 2010SeleckchemNVS8HDAC Bave Land IILai 2010SeleckchemNVS8HDAC Bave		AK-42 Ouisipostat		Arts of al. 2000	Sollockchom
New matchHDAGSDBGDBGDBGSDBGSNote of the section		PC50		Cupta at al. 2010	synthesized
Act 179-84ChoiceProductionP		Novturastat A	HDAC6	Porgman et al. 2012	ApovPio
All 11 9-94Cass I and IIAnalyz 2001; Rajkaraz and KumagAppexBio AppexBioPranobinostatCass I and IIDovorum Diemayr et al. 2010AppexBio AppexBioAll 11 79-85Cass I and IICass I and IICass I and IIAll 11 79-85Cass I and IIBiotom et al. 2005SymthesizedAll 11 79-85Cass I and IISchoor et al. 2006SymthesizedAll 11 79-85Cass I and IICass I and IICass I and IIAll 11 79-85Cass I and IILass I and IILass I and IIAll 11 79-85Cass I and IICass I and IICass I and IIBelinostatCass I and IIMall All Weber et al. 2004AppexBioM344Cass I and IIMall All Weber et al. 2001AppexBioDoxinostatCass I and IIMall All Weber et al. 2010AppexBioNaphthobydroxanic addBlack I all IIWool et al. 2007Sigma-AldrichDoxinostatCass I and IIWool et al. 2007Sigma-AldrichHydroxanic addIDAC BWool et al. 2010AppexBioMall 4Cass I and IIWool et al. 2010AppexBioMotostatCass I and IIMale et al. 2010AppexBioMotostatCass I and IIAll All All All All All All All All All			Class Land II	Vababarg at al. 2006	Apexblo
PartinotingCase i and iiPartinotic (\$8039)Case i and iiPartinotic (\$8039)Case i and iiPartinotic (\$8039)Partinotic (\$8039)		ALII/9-04		Atadia 2000: Bailumar and Kumar	ApovRio
Practinostar (sB939)Class 1 and 1NoticeApexiloSBHAClass 1 and 1Richnor et al., 2000ApexiloAL. 179-85Class 1 and 11Kilchnor et al., 2006synthesizedGrivinostarClass 1 and 11Lenser et al., 2006ApexiloGrivinostarClass 1 and 11Lenser et al., 2007ApexiloM344Class 1 and 11Heitweg et al., 2001ApexiloBellmitarClass 1 and 11Heitweg et al., 2001ApexiloBellmitarClass 1 and 11Heitweg et al., 2001ApexiloBellmitarClass 1 and 11MailPlumb et al., 2001ApexiloNominostarClass 1 and 11Kozilowski et al., 2006SpreitisCAV10603Class 1 and 11Kozilowski et al., 2008BiotechStartClass 1 and 11Kozilowski et al., 2008BiotechVAHA (Valproic acidClass 1 and 11Kozilowski et al., 2008BiotechVAHA (Valproic acidClass 1 and 11Kozilowski et al., 2008SeleckhemNW58HDAC6Class 1 and 11Kozilowski et al., 2008SeleckhemNW58HDAC6Class 1 and 11KozilowskiSeleckhemNW58HDAC6Lass 1 and 11KozilowskiSeleckhemHP08HDAC6Lass 1 and 11KozilowskiSeleckhemNW58HDAC6Lass 1 and 11KozilowskiSeleckhemNW58HDAC6Lass 1 and 11KozilowskiApexiloKilowskiLass 1 and 11Lass 1Lass 1Lass 1 <td></td> <td>Parlobiliostat</td> <td></td> <td>2016</td> <td>Арехыо</td>		Parlobiliostat		2016	Арехыо
SHM AL173-8-GLass I and IIKlamberg et al. 2006AppexiloAL173-8-GLass I and IIRichon et al. 2005SphekioSAHA (Vorinostat)Class I and IILeon et al. 2005ApexiloM344Class I and IILeon et al. 2005ApexiloM344Class I and IIMandE-Webre et al. 2004ApexiloResminostatClass I and IIMandE-Webre et al. 2007ApexiloBelinostatClass I and IIMandE-Webre et al. 2007ApexiloNaphtholydroxamic acidDOXGKrenntrube et al. 2007Sgm-AldrichDroxinostatClass I and IIKrenntrube et al. 2007Sgm-AldrichDroxinostatClass I and IIKozikowski et al. 2008Santa CruzMartinovamateClass I and IIKozikowski et al. 2008Santa CruzhydroxamateClass I and IIMai et al. 2005SelecherWAHA (Valproic acidClass I and IIMai et al. 2008Santa CruzhydroxamateClass I and IIMai et al. 2008Santa CruzhydroxamateClass I and IIApexiloSanta CruzhydroxamateClass I and IIApexiloSelecherABHAClass I and IIApexiloSelecherNWS8HDAC Is 2Water et al. 2010SphekiloKocilinostatHDAC6Lee et al. 2013ApexiloBUDC5ApexiloList al. 2018ApexiloBUDC6Kas I and IIKocilinostatApexiloCuDC-101Class I and IIList al. 2013Apexilo		Pracinostat (SB939)		Novotny-Diermayr et al., 2010	ApexBio
Ar. 11.79-85Class I and IIRainborg et al., 2006SynthesizedSAHA (Vorinostat)Class I and IIIchon et al., 2005ApexBioGrivnostatClass I and IIIchon et al., 2001ApexBioM344Class I and IIHeltweg et al., 2004ApexBioResminostatClass I and IIHeltweg et al., 2003ApexBioResminostatClass I and IIPlumb et al., 2003; Thompson, 2014ApexBioNaphtholydroxamic addHDAC8Wood et al., 2010ApexBioDroxinostatClass I and IIWood et al., 2010ApexBioVAHA (Valproic acidClass I and IIWood et al., 2010ApexBioHydroxamate)Kass I and IIKass I al., 2010Santa CruzWidtholydroxamic adiClass I and IIAndrews et al., 2010SynthesizedHydroxamate)Kass I and IIAndrews et al., 2000synthesizedWidtholydroxamic adiClass I and IIAndrews et al., 2000synthesizedHydroxamate)Kass I and IIAndrews et al., 2010synthesizedWidtholydroxamic adiClass I and IIAndrews et al., 2010synthesizedHydroxamate)Kass I and IIAndrews et al., 2010synthesizedWidtholydroxamic adi I adi DAC6Butler et al., 2010SpeckIochemHydroxamic adi I adi DAC6Butler et al., 2010ApexBioCyclicRoclinostatClass I and IIApexBioHydroxamic adi I DAC6Balsabufornamine et al., 2003ApexBioHydroxamic adi I DAC6Class I and IIA		SBHA		Kichon et al., 1998	ApexBio
SHAR (vormostar)Class 1 and 11Bochi et al., 2005ApexBioGivinostarClass 1 and 11Looi et al., 2005ApexBioM344Class 1 and 11Hellveg et al., 2004ApexBioBelinostatClass 1 and 11Mandl-Vober et al., 2010ApexBioBelinostatClass 1 and 11Mandl-Vober et al., 2003Timpson, 2014ApexBioClass 1 and 11Mandl-Vober et al., 2003Sigma-AldrichDroxinostatClass 1 and 11Korelowski et al., 2006ApexBioCAV10603Class 1 and 11Korelowski et al., 2008Santa CruzMode et al., 2010ApexBioSanta CruzBiotechMode et al., 2017Class 1 and 11Fass et al., 2010Santa CruzMode et al., 2018Class 1 and 11Fass et al., 2010Santa CruzMode et al., 2018Class 1 and 11Fass et al., 2010Santa CruzMode et al., 2018Class 1 and 11Fass et al., 2010Santa CruzMode et al., 2018Class 1 and 11Fass et al., 2010Santa CruzMode et al., 2018Mait et al., 2018Santa CruzBiotechMode et al., 2018Mait et al., 2018Santa CruzBiotechHPOBHDAC faBalter et al., 2010SynthesizedNWS8HDAC faBalter et al., 2010ApexBioBerzamideEGR (epidermal growth factor receptor)Here et al., 2010ApexBioPC-140Class 1 and 11Lai et al., 2012SelleckchemHPOBHDAC6Balter et al., 2013ApexBio </td <td></td> <td>AL-11/9-85</td> <td></td> <td>Kannberg et al., 2006</td> <td>synthesized</td>		AL-11/9-85		Kannberg et al., 2006	synthesized
CurveClass 1 and 1Lefent ef al., 2005Apex8ioM344Class 1 and 11Heltweg et al., 2004Apex8ioRestminostatClass 1 and 11Plumb et al., 2003Apex8ioNaphthohydroxani addClass 1 and 11Plumb et al., 2003Mapex8ioNaphthohydroxani addClass 1 and 11Wood et al., 2004Apex8ioNaphthohydroxani addClass 1 and 11Wood et al., 2007Sigma-AldrichNaphthohydroxani addClass 1 and 11Wood et al., 2008Santa CruzMC-1568Class 1 and 11Mai et al., 2005SelleckchemMC-1568Class 1 and 11Andrews et al., 2000synthesizedMC-1568Class 1 and 11Andrews et al., 2000synthesizedMC-1568Class 1 and 11Andrews et al., 2000synthesizedNWS8HDAC 18 2SelleckchemsynthesizedNWS8HDAC 18 2SelleckchemsynthesizedHDC6Class 1 and 11Le et al., 2010specificNWS8HDAC 18 2SelleckchemSelleckchemNWS8HDAC 18 2SelleckchemSelleckchemHDC6Class 1 and 11La et al., 2010Apex8ioCloculintsrintHDAC6SelleckchemSelleckchemHDC6Class 1 and 11La et al., 2010Apex8ioHDC7Class 1 and 11SelleckchemSelleckchemHDC6Class 1 and 11SelleckchemSanta CruzBR073954HDAC6SelleckchemSelleckchemHDC6Class 1 and 11S		SAHA (Vorinostat)		Richon et al., 1998; Iwamoto et al., 2013	Арехвіо
M344Class I and IIHeltweg et al., 2004ApexBioResminostatClass I and IIMadd/Woher et al., 2010ApexBioBelinostatClass I and IIRenninuble et al., 2003, Thompson, 2014ApexBioDroxinostatClass I and IIRenninuble et al., 2003, Thompson, 2014ApexBioCAV10603Class I and IIKrennhube et al., 2008, Sinomeson, 2014ApexBioDroxinostatClass I and IIKrennhube et al., 2008, Sinomeson, 2014ApexBioMC-1568Class I and IIFass et al., 2010Santa CruzMC-1568Class I and IIFass et al., 2010SynthesizedMC-1568Class I and IIMai et al., 2005SelleckchemMC-1568Class I and IIMai et al., 2005SelleckchemMC-1568Class I and IIMai et al., 2010synthesizedNWS8HDAC 1k 2Wheatley et al., 2010synthesizedHP06HDAC 6Buter et al., 2010synthesizedHP06HDAC6Le et al., 2013ApexBioBR073954HDAC6 Cand HDAC8Dison et al., 2013ApexBioRCUID-101Class I and IILis et al., 2010ApexBioPC24051HDAC6Balastarin AHDAC6Balastarin APC4051HDAC6Balastarin AApexBioPC14051HDAC6Balastarin AApexBioPC14051HDAC6Balastarin AApexBioPC24051HDAC6Balastarin AApexBioPC14051HDAC6Balastarin AApexBioPC140		Givinostat		Leoni et al., 2005	Арехвіо
ResiminostatClass I and IIMand-Weber et al., 2010ApextioBelinostatClass I and IIPlumbe et al., 2037Sigma-AldrichNaphthohydroxanic acidHDAC8Wood et al., 2010ApextioCAV10603Class I and IIWood et al., 2010ApextioVAHA (Valproic acidClass I and IIKozikowski et al., 2008Sinta CruzJydroxanate)Wood et al., 2010Sinta CruzBiotechMc1-1568Class I and IIAndrews et al., 2000synthesizedMvV58HDAC 1&2Wheatey et al., 2000synthesizedNVV58HDAC 1&2Wheatey et al., 2010selfecknemHPOBHDAC6Lee et al., 2013ApextioHPOBHDAC6Lee et al., 2013ApextioCUDC-101Class I and IILait et al., 2010SelfecknemHPOBHDAC6Lee et al., 2013ApextioCUDC-101Class I and IILait et al., 2010ApextioHER2 (human epidermal growth factor receptor)HER2 (human epidermal growth factor receptor)Santo et al., 2013ApextioHER2 (human epidermal growth factor receptor)Hut et al., 2000ApextioBiotechMoctinostatClass I and IIHut et al., 2001ApextioHotesHDAC6Balasubramanian et al., 2008ApextioHut et al., 2010ApextioHut et al., 2010ApextioHittigHDAC6Santo et al., 2002Santo et al., 2003ApextioHut et al., 2003ApextioApextioSanta CruzB		M344		Heltweg et al., 2004	Арехвіо
Naphtholydroxamic acidClass I and IIPlumb et al., 2003Kompokino 2014ApexbioNaphtholydroxamic acidClass I and IIKorenhrubec et al., 2000ApexbioCAY10603Class I and IIKorenhrubec et al., 2008Santa CruzNAPAClass I and IIKorenhrubec et al., 2008Santa CruzWidroxamate)Class I and IIKorenhrubec et al., 2009Sigma-AldrichMC-1568Class I and IIAndrews et al., 2000SynthesizedMC-1568Class I and IIAndrews et al., 2000SynthesizedNW53HDAC I & 2Wheatey et al., 2010SynthesizedTubacinHDAC6Butler et al., 2010SelleckchemHP08HDAC6Butler et al., 2010SelleckchemHP08HDAC6Close et al., 2013ApexBioCUDC-101Class I and IILai et al., 2010ApexBioECRR (epidemal growth factor receptor)HER2 (human epidermal growth factor receptor)Santa et al., 2010HER2 (human epidermal growth factor receptor 2)HER2 (human epidermal growth factor receptor 2)SelleckchemCyclicRoniclepsinClass I and IIHuce al., 2003ApexBioCyclicRoniclepsinClass I and IIParter al., 2008ApexBioBenzamidesEntinostatClass I and IIParter al., 2008ApexBioCyclicRoniclepsinClass I and IIParter al., 2008ApexBioCyclicRoniclepsinClass I and IIParter al., 2008ApexBioDisulfidePast I al., 2005<		Resminostat	Class I and II	Mandl-Weber et al., 2010	ApexBio
Napithohydroxamic acid Droxinostat Class I and IIMode S Class I and IIKrenntrubec et al., 2007Sigma-Addrch ApexBio Santa Cruz BiotechVAHA (Valproic acid hydroxamte)Class I and IIKozikowski et al., 2008Santa Cruz BiotechWAHA (Valproic acid hydroxamte)Class I and IIFass et al., 2010Santa Cruz BiotechMc-1568Class I and IIMai et al., 2000synthesizedABHAClass I and IIAnderws et al., 2010synthesizedNVS8HDAC 18.2Wheatley et al., 2010synthesizedNVS8HDAC 6Euter et al., 2010synthesizedTubacinHDAC6Lee et al., 2013ApexBioCUDC-101Class I and IILee et al., 2010ApexBioCUDC-101Class I and IILee et al., 2010ApexBioCuditionstatHDAC6Santo et al., 2010ApexBioTubastatin AHDAC6HDAC6Santo et al., 2010ApexBioCyclicRomidepsinClass I and IIClass I and IIApexBioCyclicRomidepsinClass I and IIApexBioApexBioCyclicRomidepsinClass I and IIApexBioApexBioCyclicRomidepsinClass I and IIApexBioApexBioTubastatin AHDAC6Class I and IIApexBioApex		Belinostat	Class I and II	Plumb et al., 2003; Thompson, 2014	АрехВю
DroxinostatClass I and IIWood et al., 2010ApexBioCAY10053Class I and IIKolzkowski et al., 2008Santa CruzBiotechVAHA (Valproic acidClass I and IIFass et al., 2010Santa CruzMc-1568Class I and IIAndrews et al., 2000SynthesizedMc-1568Class I and IIAndrews et al., 2000SynthesizedMc-1568Class I and IIAndrews et al., 2000SynthesizedMc-1568Class I and IIAndrews et al., 2010SelleckchemMK-15764HDAC5Butter et al., 2010SelleckchemNW58HDAC6Lee et al., 2013ApexBioTubacinHDAC6Butter et al., 2013ApexBioBRD73954HDAC6 and HDAC8Olson et al., 2013ApexBioCUDC-101Class I and IILai et al., 2010Santa CruzBRD73954HDAC6Butter et al., 2010ApexBioCyclicRonidepsinClass I and IILai et al., 2012SelleckchemTubastatin AHDAC6Butter et al., 2010Santa CruzBiotechMoctinostatClass IFurumai et al., 2008Santa CruzBiotechCyclicRonidepsinClass I and IIBalasubramanian et al., 2008ApexBioMoctentostatClass IGas IHuteg 2015BiotechMoctentostatClass IGas IMoctentostaApexBioThioesterVSI70Class I and IIHoteGApexBioPisulfichPasanamapiin AClass IMoctentostaA		Naphthohydroxamic acid	HDAC8	Krennhrubec et al., 2007	Sigma-Aldrich
CAV10603Class I and IIKozikowski et al., 2008Santa Cruz BiotechVAHA (Valproic acid hydroxamate)Class I and IIFass et al., 2010Santa Cruz BiotechMc1568Class I and IIMai et al., 2005Selleckchem ABHAABHAClass I and IIAndrews et al., 2000synthesizedNV58HDAC 1& 2Whealey et al., 2010synthesizedInterve et al., 2011ApexBioSelleckchemHP08HDAC6Lee et al., 2013ApexBioHP08HDAC6Lee et al., 2013ApexBioCUDC-101Class I and IILai et al., 2010ApexBioCUDC-101Class I and IILai et al., 2010ApexBioHER2 (human epidermal growth factor receptor 2)HER2 (human epidermal growth factor receptor 2)Santa Cruz BiotechPC1-34051HDAC6Butier et al., 2010ApexBioPC1-34051HDAC6Butier et al., 2003ApexBioBenzamidesEntinostatClass I and IIHutley 2015BenzamidesRocilinostatClass I and IIHutley 2015ThioesterKD5170Class I and IIHassig et al., 2006ApexBioDisulfidePsamaplin AClass I and IIHassig et al., 2006ApexBioThiolateTCS HDAC62bbHDAC6Butier et al., 2007Santa CruzBiotechHDAC6Gas I and IIHassig et al., 2006ApexBioCyclicApicklinHDAC6Butier et al., 2006ApexBioCyclicRodicpsinClass I and II <t< td=""><td></td><td>Droxinostat</td><td>Class I and II</td><td>Wood et al., 2010</td><td>ApexBio</td></t<>		Droxinostat	Class I and II	Wood et al., 2010	ApexBio
VHA (Valproic acid hydroxamate)Class 1 and IIFass et al, 2010Sainta Cruz Biorech BiorechMC -1568Class I and IIMai et al, 2005SelleckchemABHAClass I and IIAndrews et al, 2000synthesizedNWS5HDAC 18 2Wheatty et al, 2010synthesizedIbboxHDAC 18 2Wheatty et al, 2010synthesizedNWS6HDAC 6Butter et al, 2013ApexBioBBD73954HDAC6Let et al, 2013ApexBioCUDC-101Class 1 and IILai et al, 2010ApexBioECFK (epidemal growth factor receptor) PCI-34051HDAC6Santo et al, 2012SelleckchemPCUDC-101Class 1 and IILai et al, 2010ApexBioCyclicRomilepsinHDAC6Santo et al, 2012SelleckchemPCI-34051HDAC6Butter et al, 2010ApexBioPCI-34051HDAC6Santo et al, 2012SelleckchemMercilinostatHDAC6Butter et al, 2010ApexBioPCI-34051HDAC6Santo CruzBiotechPCI-34051HDAC6Butter et al, 2003ApexBioMorecilinostatClass 1 al IIHutel 2015ApexBioThiolateVSD170Class 1 and IIBaud et al, 2006ApexBioPrivater (AN-9)HDAC6Suruki et al, 2006ApexBioPrivater (AN-9)HDAC6Suruki et al, 2006ApexBioPrivater (AN-9)HDAC6Suruki et al, 2006ApexBioPrivater (AN-9)HDAC6Suruki et al, 2006Ap		CAY10603	Class I and II	Kozikowski et al., 2008	Santa Cruz
VirA (Valproiz acid)Class I and IIPlast et al., 2010Santa Chi2hydroxamate)Mai et al., 2005SelleckchemMC-1568Class I and IIMai et al., 2000synthesizedABHAClass I and IIAndrews et al., 2010synthesizedNWS8HDAC 18.2Wheatley et al., 2010synthesizedIbboxHDAC6Butler et al., 2013ApexBioTubacinHDAC6Lee et al., 2013ApexBioHP08HDAC6 and HDAC8Olson et al., 2010ApexBioCUDC-101Class I and IILai et al., 2010ApexBioCUDC-101Class I and IILai et al., 2010ApexBioCUDC-101Class I and IIBatter et al., 2010ApexBioCyclicRocilinostatHDAC6Butler et al., 2010ApexBioPCI-34051HDAC6Butler et al., 2010ApexBioPCI-34051HDAC8Balasubramanian et al., 2008Santa CruzBenzamidesEntinostatClass I and IIHurley 2015Balasubramanian et al., 2008MocetinostatClass I and IIHassig et al., 2008ApexBioDisulfidePsammaplin AClass I and IIHassig et al., 2006ApexBioDisulfidePsammaplin AClass I and IIBaud et al., 2006ApexBioCyclicApicidinHDAC6Suzuki et al., 2006ApexBioCyclicApicidinHDAC6Suzuki et al., 2006ApexBioDisulfidePsammaplin AClass I and IISinta CruzBiotech <trr>Piviar</trr>			Class Land II	E	Biotech
MC-1568 ABHAClass IaMai et al., 2005 ABHASelleckchemABHAClass I and IIAndrews et al., 2000synthesizedNW58HDAC 1& 2Wheatley et al., 2010synthesizedNW58HDAC6Butter et al., 2013ApexBioHDOBHDAC6Lee et al., 2013ApexBioBRD73954HDAC6 and HDAC8Olson et al., 2013ApexBioCUDC-101Class I and IILie et al., 2010ApexBioECRF (epidermal growth factor receptor)HER2 (human epidermal growth factor receptor 2)Santo et al., 2012SelleckchemTubastatin AHDAC6Butter et al., 2010ApexBioApexBioCyclicRomidepsinClass I and IILie et al., 2010ApexBioCyclicRomidepsinClass IFurumai et al., 2008ApexBiodepsiperiteHDAC8Butter et al., 2010ApexBioForeinostatHDAC6Butter et al., 2010ApexBiodepsiperiteClass I and IIFurumai et al., 2008ApexBioBiotechClass I and IIHurdey 2015Santa CruzBiotechClass I and IIHassig et al., 2006ApexBioDisulfideParammaplin AClass I and IIHassig et al., 2006ApexBioCyclicApicidinHDAC6Santa CruzBiotechThioesterKDS170Class I and IIHassig et al., 2006ApexBioCyclicApicidinHDAC6Santa CruzBiotechFinolatCS HDAC620bHDAC6Santa CruzBi		VAHA (Valproic acid		Fass et al., 2010	Santa Cruz
Mc1 1568Class I and IIMait et al., 2005SelieckChemABHAClass I and IIAndrews et al., 2000synthesizedNW58HDAC 1& 2Wheatley et al., 2010synthesizedNW58HDAC 1& 2Wheatley et al., 2010synthesizedHDAGHDAC6Butter et al., 2010SelleckchemHPOBHDAC6Lee et al., 2013ApexBioBRD73954HDAC6 and HDAC8Olson et al., 2013ApexBioCUDC-101Class I and IILai et al., 2010ApexBioECFR (epidermal growth factor receptor)HER2 (human epidermal growth factor receptor 2)SelleckchemHER2 (human epidermal growth factor receptor 2)HER2 (human epidermal growth factor receptor 2)SelleckchemVolastin AHDAC6Butter et al., 2010ApexBioPCI-34051HDAC8Balasubramanian et al., 2008Santa CruzBenzamidesEntinostatClass I and IIHassig et al., 2002; Barbarotta and ApexBioMocetinostatClass I and IIHassig et al., 2003ApexBioThioatetClass I and IIHassig et al., 2008; ApexBioApexBioDisulfidePsammaplin AClass I and IIHassig et al., 2006; ApexBioApexBioFattrapeptideClass I and IIHDAC1; Anti-protozoan activityJones et al., 2006; ApexBioApexBioFattrapeptideCyclicApicidinHDAC1; Anti-protozoan activityJones et al., 2007Sigma-AldrichFattrapeptideLai et al., 2007Sigma-AldrichHotC1; ApexBioSigma-Aldrich		nydroxamate)		N 1 2005	Biotech
AbtrAClass I and IIAndrews et al., 2000synthesizedNVS8HDAC Ia 2Wheatley et al., 2010synthesizedTubacinHDAC6Butler et al., 2010SynthesizedHPOBHDAC6Lee et al., 2013ApexBioBRD73954HDAC6 and HDAC8Olson et al., 2013ApexBioCUDC-101Class I and IILai et al., 2010ApexBioEGR (epidermal growth factor receptor)HEE2 (human epidermal growth factor receptor 2)Santo et al., 2012SelleckchemHEX2 (human epidermal growth factor receptor 2)HEX2 (human epidermal growth factor receptor 2)Santo et al., 2012SelleckchemVoltastatin AHDAC6Butler et al., 2010ApexBioApexBioPCI-34051HDAC8Balasubramanian et al., 2008ApexBioCyclicRomidepsinClass IFurumai et al., 2003ApexBioBenzamidesEntinostatClass IFurumai et al., 2008ApexBioDisulfidePsammaplin AClass IFournel et al., 2008ApexBioDisulfidePsammaplin AClass I and IIHassig et al., 2006ApexBioCyclicApicidinHDAC6Suzuki et al., 2006; Darkin-Rattray et al., ApexBioBiotechThioasterKD5170Class I and IIHassig et al., 2006; Darkin-Rattray et al., ApexBioSigma-AldrichThiolateTCS HDAC620bHDAC6Suzuki et al., 2006; Darkin-Rattray et al., ApexBioSigma-AldrichPrivare (AN-9)HibAco hyperacelylationRabizach et al., 2007Sigma-Aldrich <td< td=""><td></td><td>MC-1568</td><td>Class IIa</td><td>Mai et al., 2005</td><td>Selleckchem</td></td<>		MC-1568	Class IIa	Mai et al., 2005	Selleckchem
NWS8HDAC 18 2Wheatley et al., 2010synthesizedTubacinHDAC6Butler et al., 2010SelleckchemHP0BHDAC6Lee et al., 2013ApexBioBRD73954HDAC6 and HDAC8Olson et al., 2013ApexBioCUDC-101Class I and IILai et al., 2010ApexBioEGRR (epidermal growth factor receptor)HEZ (human epidermal growth factor receptor 2)Santo et al., 2012SelleckchemRocilinostatHDAC6Butler et al., 2010ApexBioPCI-34051HDAC8Balasubramanian et al., 2008Santa CruzdepsipeptideEntinostatClass IFurumai et al., 2003ApexBioMocetinostatClass IFurumai et al., 2003ApexBioMocetinostatClass IFurumai et al., 2003ApexBioDisulfidePaanmaplin AClass IFurumai et al., 2008ApexBioDisulfidePaanmaplin AClass I and IIHassig et al., 2008ApexBioDisulfidePaanmaplin AClass I and IIBaud et al., 2017, Santar cruzBiotechFatty acidsValproic acidClass I and IIPiel et al., 2006ApexBioFatty acidsValproic acidClass I and IIPiel et al., 2007Santa CruzFatty acidsValproic acidClass I and IIPiel et al., 2007Sigma-AldrichPivanex (AN-9)Histone hyperacetylationRabizadeh et al., 2007Sigma-AldrichPivanex (AN-9)Histone hyperacetylationRabizadeh et al., 2007Sigma-AldrichPivanex (AN-9)		ABHA		Andrews et al., 2000	synthesized
I ubacinHDAC6Butler et al., 2010SellecknemHPOBHDAC6Lee et al., 2013ApexBioBRD73954HDAC6 and HDAC8Olson et al., 2013ApexBioCUDC-101Class I and IILai et al., 2010ApexBioEGFR (epidermal growth factor receptor)HER2 (human epidermal growth factor receptor 2)Santo et al., 2012SelleckchemHER2 (human epidermal growth factor receptor 2)HER2 (human epidermal growth factor receptor 2)Santo et al., 2010ApexBioCyclicRomidepsinHDAC6Butler et al., 2010ApexBioApexBioCyclicRomidepsinClass IHDAC6Butler et al., 2003ApexBiodepsipeptideHDAC8Balasubramanian et al., 2003ApexBioBenzamidesEntinostatClass IHuret 2015HoreBenzamidePortmel et al., 2003ApexBioApexBioThioesterKD5170Class I and IIHassig et al., 2006ApexBioDisulfidePammaplin AClass I and IIHassig et al., 2006ApexBioCyclicApicdinHDAC6Suzuki et al., 2006ApexBioCyclicApicidinHDAC6Suzuki et al., 2006ApexBioCyclicApicdinHDAC6Suzuki et al., 2007Sigma-AldrichSequiterypenteIDAC6Suzuki et al., 2006ApexBioCyclicApicidinHDAC6Suzuki et al., 2007Sigma-AldrichSequiterypenteIDAC6Suzuki et al., 2007Sigma-AldrichSequiterypenteIDAC6 </td <td></td> <td>NVV58</td> <td>HDAC 1& 2</td> <td>Wheatley et al., 2010</td> <td>synthesized</td>		NVV58	HDAC 1& 2	Wheatley et al., 2010	synthesized
HPOBHDAC6HDAC6Lee et al., 2013ApexBioBRD73954HDAC6Olson et al., 2013ApexBioCUDC-101Class I and IILai et al., 2010ApexBioEGFR (epidermal growth factor receptor)HER2 (human epidermal growth factor receptor 2)Santo et al., 2012SelleckchemHER2 (human epidermal growth factor receptor 2)Butter et al., 2010ApexBioCyclicRomidepsinHDAC6Butter et al., 2010ApexBioPCI-34051HDAC8Balasubramanian et al., 2008Santa CruzBenzamidesEntinostatClass IFurumai et al., 2002; Barbarotta and Hurley 2015ApexBioBenzamidesEntinostatClass IHurley 2015ApexBioMocetinostatClass IHurley 2015ApexBioApexBioThioesterKD5170Class I all IIHassig et al., 2008ApexBioDisulfidePsamaplin AClass ISuzuki et al., 2006; Darkin-Rattray et al., 2007Santa Cruz BiotechThiolateTCS HDAC620bHDAC6Suzuki et al., 2006; Darkin-Rattray et al., 208; Darkin-Rattray et al., 208; Darkin-Rattray et al., 208; Darkin-Rattray et al., 208; Darkin-Rattray et al., 2007Sigma-AldrichThiolateTCS HDAC620bHDAC6Suzuki et al., 2007Sigma-AldrichThiolateClass I and IIHDAC1; Anti-protozoan activityJones et al., 2007; Fass et al., 2010; Sigma-AldrichThiolateFivanex (AN-9)Histone hyperacetylationRabizadeh et al., 2007; Sans et al., 2007Sigma-AldrichSequiterpeneparthenolide <td></td> <td>lubacin</td> <td>HDAC6</td> <td>Butler et al., 2010</td> <td>Selleckchem</td>		lubacin	HDAC6	Butler et al., 2010	Selleckchem
BKD 73954HDAC6 and HDAC8Olson et al., 2013ApexBioCUDC-101Class I and IIiet al., 2010ApexBioEGFR (epidermal growth factor receptor)HER2 (human epidermal growth factor receptor 2)Santo et al., 2012SelleckchemRocilinostatHDAC6Butler et al., 2010ApexBioPCI-34051HDAC6Butler et al., 2010ApexBioGyclicRomidepsinClass IFurumai et al., 2002Santa CruzBenzamidesEntinostatClass IFurumai et al., 2002ApexBioMocetinostatClass IHuley 2015ApexBioApexBioDisulfidePsammaplin AClass I and IIHassig et al., 2008ApexBioDisulfidePsammaplin AClass I and IIHassig et al., 2008ApexBioCyclicApicdinHDAC6Suzuki et al., 2008ApexBioDisulfidePsammaplin AClass I and IIBaud et al., 2012; Kim et al., 2007Santa CruzBiotechHDAC6Suzuki et al., 2006ApexBioCyclicApicidinHDAC6Suzuki et al., 2006ApexBioCyclicApicidinHDAC6Suzuki et al., 2007Sigma-AldrichSesquiterpenepartenoliceDepletes HDAC1 but not other class I/II HDACsGopaled et al., 2007Sigma-AldrichSesquiterpenepartenoliceDepletes HDAC1 but not other class I/II HDACsGopaled et al., 2007Sigma-AldrichSesquiterpenepartenoliceDepletes HDAC1 but not other class I/II HDACsGopaled et al., 2007Sigma-Aldrich		HPOB	HDAC6	Lee et al., 2013	Арехвіо
CUDC-101Class I and IILai et al., 2010ApexBioECRF (epidermal growth factor receptor) HER2 (human epidermal growth factor receptor 2) HER2 (human epidermal growth factor receptor 2) HER2 (human epidermal growth factor receptor 2) HER2 (human epidermal growth factor receptor 2)Santo et al., 2012SelleckhemTubastain AHDAC6Santo et al., 2010ApexBioPCI-34051HDAC8Balasubramanian et al., 2008Santa Cruz BiotechdepsipeptideClass IFurumai et al., 2002; Barbarotta and Hurley 2015ApexBioBenzamidesEntinostatClass IFurumai et al., 2003ApexBioThioesterKD5170Class I and IIHassig et al., 2008ApexBioDisulfidePsammaplin AClass IBaud et al., 2012; Kim et al., 2007Santa Cruz BiotechThiolateTCS HDAC620bHDAC6Suzuki et al., 2006; Darkin-Rattray et al., 1, 2006; Darkin-Rattray et al., 1, 2006; Darkin-Rattray et al., 1, 2007Sigma-Aldrich Sigma-AldrichFatty acidsValproic acid Pivanex (AN-9)Class I and IIPhice HDACs 1996Sigma-Aldrich Sigma-AldrichSequiterpene lactomePathenolideClass I and IIPhice I, 2007Sigma-Aldrich Sigma-AldrichPyrimidineDicyclanilInsect growth regulator: mechanism unknown-FulvaDiamino-triazineCyromazineInsect growth regulator: mechanism unknown, affects cuticleKotze and Reynolds, 1990Chem Service extensibilityBenzoyl phenylDiflubenzuronInsect growth regulator: inhibits chitin synthes		BRD73954	HDAC6 and HDAC8	Olson et al., 2013	АрехВю
ECFR (epidermal growth factor receptor)HER2 (human epidermal growth factor receptor 2)Santo et al., 2012SelleckchemHDAC6Butter et al., 2010ApexBioPCI-34051HDAC6Balasubramanian et al., 2008Santa CruzBiotechHDAC8Furumai et al., 2002; Barbarotta and Hurley 2015ApexBioCyclicRomidepsinClass IFurumai et al., 2002; Barbarotta and Hurley 2015ApexBioBenzamidesEntinostatClass IHu et al., 2003ApexBioMocetinostatClass I and IIHassig et al., 2008ApexBioDisulfidePsammaplin AClass I and IIHassig et al., 2006; Darkin-Rattray et al., 2007Santa Cruz BiotechThioesterTCS HDAC620bHDAC6Suzuki et al., 2006; Darkin-Rattray et al., 2007Santa Cruz BiotechThiolateTCS HDAC620bHDAC1; Anti-protozoan activityJones et al., 2006; Darkin-Rattray et al., 2007ApexBioCyclicApicidinHDAC1; Anti-protozoan activityJones et al., 2007; Fass et al., 2007Sigma-AldrichFatty acidsValproic acidClass I and IIPhiel et al., 2007; Fass et al., 2007Sigma-AldrichSesquiterpeneparthenolideDepletes HDAC1 but not other class I/II HDACsGopal et al., 2007Sigma-AldrichSesquiterpeneparthenolideInsect growth regulator: mechanism unknown, affects curie!Kotze and Reynolds, 1990Chem Service extensibilityBiotechInsect growth regulator: inhibits chitin synthesisHajar and Casida, 1978Chem Service </td <td></td> <td>CUDC-101</td> <td>Class I and II</td> <td>Lai et al., 2010</td> <td>АрехВю</td>		CUDC-101	Class I and II	Lai et al., 2010	АрехВю
HEAZ (numan epidermal growth factor receptor 2)Santo et al., 2012Selleckchemrubastatin AHDAC6Butler et al., 2010ApexBioPCI-34051HDAC8Balasubramanian et al., 2008Santa CruzBiotechBiotechBiotechBiotechCyclicRomidepsinClass IFurumai et al., 2002; Barbarotta and ApexBioApexBioBenzamidesEntinostatClass IHu et al., 2003ApexBioMocetinostatClass IFournel et al., 2008ApexBioDisulfidePsammaplin AClass I and IIHassig et al., 2008ApexBioDisulfidePsammaplin AClass IBaud et al., 2012; Kim et al., 2007Santa CruzBiotechItopic et al., 2007Santa CruzBiotechThiolateTCS HDAC620bHDAC6Suzuki et al., 2006; Darkin-Rattray et al., ApexBioCyclicApic cidinHDAC1; Anti-protozoan activityJones et al., 2007; Fass et al., 2010Sigma-AldrichSesquiterpenePiranex (AN-9)Histone hyperacetylationRabizadeh et al., 2007; Sast et al., 2007Sigma-AldrichSesquiterpeneparthenolideDepletes HDAC1 but not other class I/II HDACsGopal et al., 2007Sigma-AldrichBiotechInsect growth regulator: mechanism unknown, affects cutiekKotze and Reynolds, 1990Chem ServicePyrimidineDicyclanilInsect growth regulator: mechanism unknown, affects cutiekKotze and Reynolds, 1990Chem ServiceBiotechInsect growth regulator: inhibits chitin synthesisHajar and Casida, 1978 <td< td=""><td></td><td></td><td>EGFR (epidermal growth factor receptor)</td><td></td><td></td></td<>			EGFR (epidermal growth factor receptor)		
RocilinostatHDACbSanto et al., 2012SelleckchemTubastatin AHDAC6Butler et al., 2010ApexBioPCI-34051HDAC8Balasubramanian et al., 2008Santa CruzBiotechBalasubramanian et al., 2002; Barbarotta andBiotechdepsipeptideHurley 2015BenzamidesEntinostatClass IBenzamidesEntinostatClass IHurley 2015MocetinostatClass IFournel et al., 2008ApexBioDisulfidePsammaplin AClass IFournel et al., 2008ApexBioDisulfidePsammaplin AClass IBaud et al., 2012; Kim et al., 2007Santa CruzBiotechValproic acidHDAC6Suzuki et al., 2006; Darkin-Rattray et al., ApexBioApexBioCyclicApicidinHDAC1; Anti-protozoan activityJones et al., 2006; Darkin-Rattray et al., ApexBioApexBiotetrapeptideInsect growth regulator: mechanism unknownPhiel et al., 2007Santa CruzPyrimidineDicyclanilInsect growth regulator: mechanism unknown, affects cuticleKoze and Reynolds, 1990Chem ServicePyrimidineDicyclanilInsect growth regulator: mechanism unknown, affects cuticleKoze and Reynolds, 1990Chem ServicewreaUreaDiflubenzuronInsect growth regulator: mechanism unknown, affects cuticleKoze and Reynolds, 1990Chem ServiceureaUreaInsect growth regulator: mechanism unknown, affects cuticleKoze and Reynolds, 1990Chem ServiceureaUreaInsect growth regulator: mechan		D	HER2 (human epidermal growth factor receptor 2)	0 1 1 2012	C II I I
Tubastatin AHDAC6Buffer et al., 2010ApexBioPCI-34051HDAC8Balasubramanian et al., 2008Santa Cruz BiotechCyclicRomidepsinClass IFurumai et al., 2002; Barbarotta and Hurley 2015ApexBioBenzamidesEntinostatClass IHurley 2015ApexBioMocetinostatClass IFournel et al., 2003ApexBioDisotefreKD5170Class I and IIHassig et al., 2008ApexBioDisulfidePsammaplin AClass I and IIBaud et al., 2012; Kim et al., 2007Santa Cruz BiotechThiolateTCS HDAC620bHDAC6Suzuki et al., 2006ApexBioCyclicApicidinHDAC1; Anti-protozoan activityJones et al., 2006; Darkin-Rattray et al., ApexBioCyclicApicidinHDAC1; Anti-protozoan activityJones et al., 2007Sigma-AldrichPatrapacitieValproic acidClass I and IIPhiel et al., 2007Sigma-AldrichSesquiterpeneparthenolideDepletes HDAC1 but not other class I/II HDACsGopal et al., 2007Sigma-AldrichSesquiterpeneDisc(LanilInsect growth regulator: mechanism unknown-FlukaDiamino-triazineCryomazineInsect growth regulator: mechanism unknown, affects curcleKotze and Reynolds, 1990Chem ServiceBenzoyl phenylDiflubenzuronInsect growth regulator: inhibits chitin synthesisHajar and Casida, 1978Chem Service		Rocilinostat	HDAC6	Santo et al., 2012	Selleckchem
PCI-34051HDACSBalasubramanian et al., 2008Santa Cruz BiotechCyclicRomidepsinClass IFurumai et al., 2002; Barbarotta and Hurley 2015ApexBioBenzamidesEntinostatClass IHu et al., 2003ApexBioMocetinostatClass IHu et al., 2003ApexBioThioesterKD5170Class I and IIHassig et al., 2008ApexBioDisulfidePsammaplin AClass IBaud et al., 2012; Kim et al., 2007Santa CruzDisulfidePsammaplin AClass IBaud et al., 2006; Darkin-Rattray et al., ApexBioBiotechThiolateTCS HDAC620bHDAC6Suzuki et al., 2006; Darkin-Rattray et al., ApexBioApexBioCyclicApicidinHDAC1; Anti-protozoan activityJones et al., 2006; Darkin-Rattray et al., ApexBioApexBioThiolateTCS HDAc620bHDAC6Suzuki et al., 2007Sigma-AldrichFatty acidsValproic acidClass I and IIPhiel et al., 2007Sigma-AldrichPivanex (AN-9)Histone hyperacetylationRabizadeh et al., 2007Santa CruzBiotechDepletes HDAC1 but not other class I/II HDACsGopal et al., 2007Santa CruzOrmmercial biverfulInsect growth regulator: mechanism unknown-FlukaDiamino-triazineCyromazineInsect growth regulator: mechanism unknown, affects curicleKotze and Reynolds, 1990Chem ServiceBenzoyl phenylDiflubenzuronInsect growth regulator: inhibits chitin synthesisHajjar and Casida, 1978Chem Service <td></td> <td>Tubastatin A</td> <td>HDAC6</td> <td>Butler et al., 2010</td> <td>АрехВю</td>		Tubastatin A	HDAC6	Butler et al., 2010	АрехВю
Cyclic depsipeptideRomidepsin depsipeptideClass IFurumai et al., 2002; Barbarotta and Hurley 2015Botech ApexBioBenzamidesEntinostatClass IHu et al., 2003ApexBioMocetinostatClass IFournel et al., 2008ApexBioThioesterKD5170Class I and IIHassig et al., 2008ApexBioDisulfidePsammaplin AClass IBaud et al., 2012; Kim et al., 2007Santa Cruz BiotechThiolateTCS HDAC620bHDAC6Suzuki et al., 2006; Darkin-Rattray et al., ApexBioCyclicApicidinHDAC6Suzuki et al., 2006; Darkin-Rattray et al., ApexBioCyclicApicoic acidClass I and IIPhiel et al., 2001; Fass et al., 2010Sigma-AldrichFatty acidsValproic acidClass I and IIPhiel et al., 2007Sigma-AldrichSesquiterpeneparthenolideDepletes HDAC1 but not other class I/II HDACsGopal et al., 2007Sigma-AldrichSesquiterpeneDiscrutifiesInsect growth regulator: mechanism unknown-FlukaDiamino-triazinCiromazineInsect growth regulator: mechanism unknown, affects cut:/eKotze and Reynolds, 1990Chem ServiceBenzoyl phenylDiflubenzuronInsect growth regulator: inhibits chitin synthesisHajar and Casida, 1978Chem Service		PCI-34051	HDAC8	Balasubramanian et al., 2008	Santa Cruz
CyclicRomidepsinClass IHurday 2015Hurday 2015depsipeptideEntinostatClass IHurday 2015ApexBioBenzamidesEntinostatClass IHurday 2015ApexBioMocetinostatClass IFournel et al., 2003ApexBioDisulfidePsammaplin AClass I and IIHassig et al., 2008ApexBioDisulfidePsammaplin AClass IBaud et al., 2012; Kim et al., 2007Santa CruzDisulfideTCS HDAC620bHDAC6Suzuki et al., 2006; Darkin-Rattray et al., ApexBioApexBioCyclicApicdinHDAC1; Anti-protozoan activityJones et al., 2006; Darkin-Rattray et al., ApexBioCyclicApicidinHDAC1; Anti-protozoan activityJones et al., 2006; Darkin-Rattray et al., ApexBioFatty acidsValproic acidClass I and IIPhiel et al., 2007Sigma-AldrichPivanex (AN-9)Histone hyperacetylationRabizadeh et al., 2007Sigma-AldrichSesquiterpeneparthenolideDepletes HDAC1 but not other class I/II HDACsGopal et al., 2007Santa CruzBiotechIactoneInsect growth regulator: mechanism unknown-FlukaDiamino-triazineCyromazineInsect growth regulator: mechanism unknown, affects cuticeKotze and Reynolds, 1990Chem ServiceBenzoyl phenylDiflubenzuronInsect growth regulator: inhibits chitin synthesisHajjar and Casida, 1978Chem Service		- ··· ·			Biotech
depsipeptideHurley 2015BenzamidesEntinostatClass IHu et al., 2003ApexBioMocetinostatClass I and IIHassig et al., 2008ApexBioDisulfidePsammaplin AClass IBaud et al., 2012; Kim et al., 2007Santa CruzDisulfidePsammaplin AClass IBaud et al., 2006; Darkin-Rattray et al., ApexBioThiolateTCS HDAC620bHDAC6Suzuki et al., 2006; Darkin-Rattray et al., ApexBioCyclicApicidinHDAC1; Anti-protozoan activityJones et al., 2006; Darkin-Rattray et al., ApexBiotetrapeptideImport acidClass I and IIPhiel et al., 2001; Fass et al., 2010Sigma-AldrichSesquiterpeneparthenolideDepletes HDAC1 but not other class I/II HDACsGopal et al., 2007Saima-AldrichSesquiterpeneparthenolideDepletes HDAC1 but not other class I/II HDACsGopal et al., 2007Saima-AldrichBiotechInsect growth regulator: mechanism unknown, affects cuicleKotze and Reynolds, 1990Chem ServiceureaUiflubenzuronInsect growth regulator: inhibits chitin synthesisHajar and Casida, 1978Chem Service	Cyclic	Romidepsin	Class I	Furumai et al., 2002; Barbarotta and	ApexBio
BenzamidesEntinostatClass IHu et al., 2003ApexBioMocetinostatClass IClass IFournel et al., 2008ApexBioThioesterKD5170Class I and IIHassig et al., 2008ApexBioDisulfidePsammaplin AClass IBaud et al., 2012; Kim et al., 2007Santa CruzBiotechFournel et al., 2006ApexBioApexBioThiolateTCS HDAC620bHDAC6Suzuki et al., 2006; Darkin-Rattray et al., ApexBioCyclicApic didinHDAC1; Anti-protozoan activityJones et al., 2006; Darkin-Rattray et al., ApexBiotetrapeptideImport actidClass I and IIPhiel et al., 2001; Fass et al., 2010Sigma-AldrichFatty acidsValproic acidClass I and IIPhiel et al., 2007Sigma-AldrichPivanex (AN-9)Histone hyperacetylationRabizadeh et al., 2007Sigma-AldrichSesquiterpeneparthenolideDepletes HDAC1 but not other class I/II HDACsGopal et al., 2007Santa CruzIactoneInsect growth regulator: mechanism unknown, affects cuticleKotze and Reynolds, 1990Chem ServicePyrimidineDicyclanilInsect growth regulator: mechanism unknown, affects cuticleKotze and Reynolds, 1990Chem ServiceBenzoyl phenylDiflubenzuronInsect growth regulator: inhibits chitin synthesisHajjar and Casida, 1978Chem Service	depsipeptide			Hurley 2015	
MocetinostatClass IFournel et al., 2008ApexBioThioesterKD5170Class I and IIHassig et al., 2008ApexBioDisulfidePsammaplin AClass IBaud et al., 2012; Kim et al., 2007Santa CruzDisulfidePsammaplin AClass IBiotechBiotechThiolateTCS HDAC620bHDAC6Suzuki et al., 2006; Darkin-Rattray et al., ApexBioCyclicApicidinHDAC1; Anti-protozoan activityJones et al., 2006; Darkin-Rattray et al., ApexBiotetrapeptide19961996Fatty acidsValproic acidClass I and IIPhiel et al., 2001; Fass et al., 2001Sigma-AldrichPivanex (AN-9)Histone hyperacetylationRabizadeh et al., 2007Santa CruzlactoneDepletes HDAC1 but not other class I/II HDACsGopal et al., 2007Santa CruzlactoneDicyclanilInsect growth regulator: mechanism unknown-FlukaDiamino-triazineCyromazineInsect growth regulator: mechanism unknown, affects cuticleKotze and Reynolds, 1990Chem ServiceureaUreaNest growth regulator: inhibits chitin synthesisHajjar and Casida, 1978Chem Service	Benzamides	Entinostat	Class I	Hu et al., 2003	АрехВю
ThioesterKD5170Class I and IIHassig et al., 2008ApexBioDisulfidePsammaplin AClass IBaud et al., 2012; Kim et al., 2007Santa Cruz BiotechThiolateTCS HDAC620bHDAC6Suzuki et al., 2006; Darkin-Rattray et al., ApexBioCyclicApicidinHDAC1; Anti-protozoan activityJones et al., 2006; Darkin-Rattray et al., ApexBiotetrapeptide1996Fatty acidsValproic acid Pivanex (AN-9)Class I and II Histone hyperacetylationPhiel et al., 2001; Fass et al., 2010Sigma-Aldrich Sigma-AldrichSesquiterpeneparthenolideDepletes HDAC1 but not other class I/II HDACsGopal et al., 2007Santa Cruz Biotech2) Commercial biveffy insecticidesInsect growth regulator: mechanism unknown, affects cuticleKotze and Reynolds, 1990Chem Service extensibilityBenzoyl phenylDiflubenzuronInsect growth regulator: inhibits chitin synthesisHajjar and Casida, 1978Chem Service		Mocetinostat	Class I	Fournel et al., 2008	ApexBio
DisulfidePsammaplin AClass IBaud et al., 2012; Kim et al., 2007Santa Cruz BiotechThiolateTCS HDAC620bHDAC6Suzuki et al., 2006ApexBioCyclicApicidinHDAC1; Anti-protozoan activityJones et al., 2006; Darkin-Rattray et al., ApexBio 1996ApexBioFatty acidsValproic acidClass I and IIPhiel et al., 2001; Fass et al., 2010Sigma-AldrichPivanex (AN-9)Histone hyperacetylationRabizadeh et al., 2007Sigma-AldrichSesquiterpeneparthenolideDepletes HDAC1 but not other class I/II HDACsGopal et al., 2007Santa Cruz Biotech2) Commercial blowfly insecticidesInsect growth regulator: mechanism unknown, affects cuticleKotze and Reynolds, 1990FlukaDiamino-triazineCyromazineInsect growth regulator: inhibits chitin synthesisHajjar and Casida, 1978Chem ServiceureaureaLigar and Casida, 1978Chem ServiceLigar and Casida, 1978Chem Service	Thioester	KD5170	Class I and II	Hassig et al., 2008	ApexBio
Thiolate CyclicTCS HDAC620b ApicidinHDAC6Suzuki et al., 2006; Darkin-Rattray et al., ApexBio ApexBioCyclic tetrapeptideApicidinHDAC1; Anti-protozoan activityJones et al., 2006; Darkin-Rattray et al., ApexBio 1996Fatty acidsValproic acid Pivanex (AN-9)Class I and IIPhiel et al., 2001; Fass et al., 2010Sigma-Aldrich Sigma-AldrichSesquiterpene lactoneparthenolideDepletes HDAC1 but not other class I/II HDACsGopal et al., 2007Santa Cruz BiotechPyrimdineDicyclanilInsect growth regulator: mechanism unknown, affects cuticleKotze and Reynolds, 1990Fluka Chem ServiceBenzoyl phenyl ureaDiflubenzuronInsect growth regulator: inhibits chitin synthesisHajjar and Casida, 1978Chem Service	Disulfide	Psammaplin A	Class I	Baud et al., 2012; Kim et al., 2007	Santa Cruz
Thiolate TCS HDAC620b HDAC6 Suzuki et al., 2006 ApexBio Cyclic Apicidin HDAC6 Jones et al., 2006; Darkin-Rattray et al., ApexBio Cyclic Apicidin HDAC1; Anti-protozoan activity Jones et al., 2006; Darkin-Rattray et al., ApexBio tetrapeptide 1996 Fatty acids Valproic acid Class I and II Phiel et al., 2001; Fass et al., 2010 Sigma-Aldrich Sesquiterpene parthenolide Depletes HDAC1 but not other class I/II HDACs Gopal et al., 2007 Santa Cruz lactone Insect growth regulator: mechanism unknown – Fluka Pyrimidine Dicyclanil Insect growth regulator: mechanism unknown, affects cuticle Kotze and Reynolds, 1990 Chem Service Benzoyl phenyl Diflubenzuron Insect growth regulator: inhibits chitin synthesis Hajjar and Casida, 1978 Chem Service					Biotech
Cyclic Apicidin HDAC1; Anti-protozoan activity Jones et al., 2006; Darkin-Rattray et al., ApexBio tetrapeptide 1996 Fatty acids Valproic acid Class I and II Phiel et al., 2001; Fass et al., 2010 Sigma-Aldrich Pivanex (AN-9) Histone hyperacetylation Rabizadeh et al., 2007 Sigma-Aldrich Sesquiterpene parthenolide Depletes HDAC1 but not other class I/II HDACs Gopal et al., 2007 Santa Cruz Biotech 2) Commercial blowfly insecticides Insect growth regulator: mechanism unknown - Fluka Diamino-triazine Cyromazine Insect growth regulator: inchanism unknown, affects cuticle Kotze and Reynolds, 1990 Chem Service Benzoyl phenyl Diflubenzuron Insect growth regulator: inhibits chitin synthesis Hajjar and Casida, 1978 Chem Service	Thiolate	TCS HDAC620b	HDAC6	Suzuki et al., 2006	ApexBio
tetrapeptide 1996 Fatty acids Valproic acid Class I and II Phiel et al., 2001; Fass et al., 2010 Sigma-Aldrich Pivanex (AN-9) Histone hyperacetylation Rabizadeh et al., 2007 Sigma-Aldrich Sesquiterpene parthenolide Depletes HDAC1 but not other class I/II HDACs Gopal et al., 2007 Santa Cruz Biotech 2) Commercial blowfly insecticides Insect growth regulator: mechanism unknown – Fluka Diamino-triazine Cyromazine Insect growth regulator: mechanism unknown, affects cuticle Kotze and Reynolds, 1990 Chem Service Benzoyl phenyl Diflubenzuron Insect growth regulator: inhibits chitin synthesis Hajjar and Casida, 1978 Chem Service	Cyclic	Apicidin	HDAC1; Anti-protozoan activity	Jones et al., 2006; Darkin-Rattray et al.,	АрехВю
Fatty acids Valproic acid Class I and II Phiel et al., 2001; Fass et al., 2010 Sigma-Aldrich Pivanex (AN-9) Histone hyperacetylation Rabizadeh et al., 2007 Sigma-Aldrich Sesquiterpene parthenolide Depletes HDAC1 but not other class I/II HDACs Gopal et al., 2007 Santa Cruz Biotech Biotech Biotech Biotech Biotech Pyrimidine Dicyclanil Insect growth regulator: mechanism unknown - Fluka Diamino-triazine Cyromazine Insect growth regulator: inhibits chitin synthesis Hajjar and Casida, 1978 Chem Service	tetrapeptide			1996	
Pivanex (AN-9) Histone hyperacetylation Rabizadeh et al., 2007 Sigma-Aldrich Sesquiterpene parthenolide Depletes HDAC1 but not other class I/II HDACs Gopal et al., 2007 Santa Cruz lactone Depletes HDAC1 but not other class I/II HDACs Gopal et al., 2007 Santa Cruz 2) Commercial blowfly insecticides Pyrimidine Dicyclanil Insect growth regulator: mechanism unknown - Fluka Diamino-triazine Cyromazine Insect growth regulator: mechanism unknown, affects cuticle Kotze and Reynolds, 1990 Chem Service Benzoyl phenyl Diflubenzuron Insect growth regulator: inhibits chitin synthesis Hajjar and Casida, 1978 Chem Service	Fatty acids	Valproic acid	Class I and II	Phiel et al., 2001; Fass et al., 2010	Sıgma-Aldrich
Sesquiterpene parthenolide lactone Depletes HDAC1 but not other class I/II HDACs Gopal et al., 2007 Santa Cruz Biotech 2) Commercial blowfly insecticides Pyrimidine Dicyclanil Insect growth regulator: mechanism unknown – Fluka Diamino-triazine Cyromazine Insect growth regulator: mechanism unknown, affects cuticle Kotze and Reynolds, 1990 Chem Service extensibility Benzoyl phenyl urea Diflubenzuron Insect growth regulator: inhibits chitin synthesis Hajjar and Casida, 1978 Chem Service		Pivanex (AN-9)	Histone hyperacetylation	Rabizadeh et al., 2007	Sigma-Aldrich
lactone Biotech 2) Commercial blowfly insecticides Biotech Pyrimidine Dicyclanil Insect growth regulator: mechanism unknown - Fluka Diamino-triazine Cyromazine Insect growth regulator: mechanism unknown, affects cuticle Kotze and Reynolds, 1990 Chem Service Benzoyl phenyl Diflubenzuron Insect growth regulator: inhibits chitin synthesis Hajjar and Casida, 1978 Chem Service	Sesquiterpene	parthenolide	Depletes HDAC1 but not other class I/II HDACs	Gopal et al., 2007	Santa Cruz
2) Commercial blowity insecticides Pyrimidine Dicyclanil Insect growth regulator: mechanism unknown – Fluka Diamino-triazine Cyromazine Insect growth regulator: mechanism unknown, affects cuticle Kotze and Reynolds, 1990 Chem Service Benzoyl phenyl Diflubenzuron Insect growth regulator: inhibits chitin synthesis Hajjar and Casida, 1978 Chem Service	lactone				Biotech
Pyrimidine Dicycianii Insect growth regulator: mechanism unknown - Fluka Diamino-triazine Cyromazine Insect growth regulator: mechanism unknown, affects cuticle Kotze and Reynolds, 1990 Chem Service Benzoyl phenyl Diflubenzuron Insect growth regulator: inhibits chitin synthesis Hajjar and Casida, 1978 Chem Service	2) Commercial bl	lowny insecticides	To see the second state of		Fluid
Diamino-triazine Cyromazine Insect growth regulator: mechanism unknown, affects cuticle Kotze and Reynolds, 1990 Chem Service Benzoyl phenyl Diflubenzuron Insect growth regulator: inhibits chitin synthesis Hajjar and Casida, 1978 Chem Service	Pyrimidine	Dicycianii	Insect growth regulator: mechanism unknown	- Katas and Barrishta 1000	FIUKA
extensibility Benzoyl phenyl Diflubenzuron Insect growth regulator: inhibits chitin synthesis Hajjar and Casida, 1978 Chem Service urea	Diamino-triazine	Cyromazine	insect growth regulator: mechanism unknown, affects cuticle	Kotze and Reynolds, 1990	Cnem Service
urea Insect growth regulator: Inhibits chitin synthesis Hajjar and Casida, 1978 Chem Service	Democral where a	Diffusher mune	extensibility	United and Casida 1070	Champ Commission
	Benzoyi pnenyi	Dilubenzuron	insect growth regulator: inhibits chitin synthesis	Hajjar and Casida, 1978	chem Service
	ulea				

Switzerland) in PBS was added to the washed eggs before disrupting them by hand with a plastic pestle. The disrupted eggs were centrifuged at 250g for 1 min at 4 °C, and supernatant removed. The egg cell pellet was washed with 1000 μ L of ice cold PBS, resuspended by inversion, centrifuged at 1000g for 5 min at 4 °C, and the supernatant removed. This wash step was repeated a further 2 times. The cells were then disrupted by drawing 5 times through a 21 g needle fitted to a 1 mL syringe. The supension was centrifuged at 8000g for 20 min at 4 °C, the supernatant removed and discarded, and the pellet retained (nuclear portion). The nuclear pellet was resuspended in 2/3 of the original cell pellet volume of ice cold

nuclear extraction buffer (containing 0.5 mM DTT and protease inhibitor cocktail, Millipore, Temecula). The solution was placed on low speed roller for 1 h at 4 °C, then centrifuged at 16000g for 5 min at 4 °C, and the supernatant (the nuclear extract) transferred to a new tube. The protein concentration was measured by the method of Bradford (1976) using the Bio-Rad protein assay reagent, and bovine serum albumin as a standard. The extract was then aliquoted into separate tubes, snap-frozen in liquid nitrogen, and stored at -80 °C.

2.4. HDAC enzyme assay

A fluorometric assay kit (Sigma-Aldrich, USA) was used to measure HDAC enzyme activity in blowfly nuclear extracts, as described in the kit instructions, except that the volumes of all reagents were reduced to give a total assay volume of 27.5 µL. Each assay contained approximately 15 µg of nuclear extract protein. HDAC activity was measured in the presence or absence of HDACi. Control assays were also run in the presence of 1.25 µM trichostatin in order to calculate the amount of fluorescent product that was derived from a trichostatin-inhibitable reaction, that is, the amount of product derived from the action of HDAC enzymes alone. The assay was performed using a series of at least 4 serially-diluted working solutions of each HDACi. Duplicate assays were performed at each HDACi concentration. The fold dilutions used to generate each working solution series varied from 2-fold to 10fold, and were set (based on initial dose-finding experiments) in order to provide a dose response curve consisting of 4-6 data points. The % inhibition of HDAC activity was calculated for each concentration of HDACi added to the reaction. The enzyme assay dose-response data were analysed with GraphPad Prism[®] software using non-linear regression, with the 'variable slope' option selected, in order to calculate IC50 values (with 95% Confidence Intervals) representing the concentration of inhibitor required to reduce the HDAC activity of the nuclear extract by 50%.

2.5. Larval and enzyme assay comparisons

We performed a non-parametric (Spearman) correlation analysis in GraphPad Prism[®] in order to examine the relationship between the effects of HDACi in inhibiting blowfly larval development and inhibiting nuclear extract HDAC enzyme activity. In addition, in order to examine the relationship between the blowfly bioassay data and the reported inhibitory effects of the HDACi against specific human HDAC enzymes, we performed a correlation analysis using the bioassay data and IC₅₀ values reported in the scientific literature for the HDACi against human HDAC enzymes (see Supplementary Table 1). While blowflies are known to possess HDAC1, 3, 4, 6 and 11, (Kotze et al., 2015), the analysis was only performed with human HDAC1, 3, 4 and 6 as insufficient inhibition data was available for an analysis of inhibitory effects on human HDAC11. For the correlation analysis, we grouped HDAC 1 and 3 together as Class I HDAC enzymes, and HDAC4 and 6 together as Class II HDAC enzymes.

3. Results

Forty HDACi compounds were investigated for inhibition of the growth of blowfly larvae, with their activities reported in Table 2 as inhibition of larval weight gain and pupation (µg/assay). For comparison, the toxicities of three commercial blowfly insecticides are also reported in Table 2. The most potent inhibitor of blowfly larval growth was the depsipeptide romidepsin, which was more potent, or as potent as, the commercial insecticides: 10-fold more potent than cyromazine, 2-fold more potent than diflubenzuron, and equipotent with dicyclanil (Table 2, Figs. 1 and 2). The most potent hydroxamic acids were trichostatin, CUDC-907, AL179-3b and AR-42: approximately 10-fold less potent than cyromazine, and approximately 50-100-fold less potent than diflubenzuron and dicyclanil. Also showing marked activity ($IC_{50} < 100 \mu g/assay$) were the thioester compound KD5170, the disulfide compound Psammaplin A (which is a prodrug that forms a thiolate much like romidepsin), and the cyclic tetrapeptide apicidin. Many of the compounds, including 13 of the hydroxamic acids, the two fatty acids (valproic acid and AN-9), and the single sesquiterpene lactone (parthenolide) showed little or no insecticidal activity ($IC_{50} > 1000 \ \mu g$ /assay).

Comparisons between the larval weight gain and pupation IC_{50} for the commercial insecticides showed that the two values were within 2-fold of each other. For 7 of the 8 most active HDACi (larval $IC_{50} < 100 \mu g/assay$, Fig. 2), the variation between the larval and pupation IC_{50} values was also within a 2-fold range. The two values were approximately equal for CUDC-907 and AR-42, while within 2-fold for trichostatin, AL1179-3b, romidepsin and KD5170. On the other hand, the pupation IC_{50} for apicidin was 6-fold higher than for larval weight gain.

The HDACi were also investigated for inhibition of HDAC activity in nuclear extracts from blowfly eggs (Table 3), with representative dose-response curves shown in Fig. 3 (some of the compounds shown in Tables 1 and 2 were not examined in nuclear extract assays as insufficient material was available). As with the insecticidal assays, romidepsin was the most potent inhibitor of HDAC activity. This compound was approximately 600-fold more potent than the second most-active compound, quisinostat, and about 1000-fold more potent than trichostatin. The hydroxamic acids that were the most active in the blowfly larval bioassay were among the most potent enzyme inhibitors (IC50 0.016-0.212 µM for trichostatin, CUDC-907 and AR-42). A number of hydroxamic acids that were significant HDAC enzyme inhibitors in the nuclear extracts $(IC_{50} < 0.3 \ \mu M)$ had low potency in the larval bioassay (e.g. panobinostat, givinostat, belinostat: larval IC₅₀ 295, 477, and 740 µg/ assay, respectively). Among the other compounds highlighted above for their insecticidal activity (from Fig. 2), all showed significant potency in inhibiting the HDAC enzyme activity of the nuclear extract (all IC₅₀ < 1 μ M).

The relationship between larval bioassay IC₅₀ and nuclear extract HDAC inhibition IC₅₀ is shown in Fig. 4 (Fig. 4A shows whole data set, Fig. 4B shows data points with extract HDAC inhibition IC₅₀ < 2.0 μ M only). Analysis of the whole data set (Fig. 4A), revealed that the two assay parameters were significantly correlated (Spearman correlation coefficients shown on Figure panels). Despite this, some differences between the two measurements were apparent, with larval weight IC₅₀ values of 1000 (n = 14) corresponding to a range of nuclear extract activities from 0.032 μ M (CUDC-101) to > 100 μ M (six compounds). Importantly, low larval weight IC₅₀ values (<100 μ g/assay) did not occur alongside high nuclear extract IC₅₀. Fig. 4B illustrates this, with the most active insecticidal compounds all being potent inhibitors of HDAC activity in blowfly nuclear extracts (IC₅₀ < 0.5 μ M).

We also examined the relationship between published IC₅₀ values for inhibition of human HDAC enzymes by the HDACi used in this study with their activity in inhibiting blowfly larval development. The analysis was restricted to just the human HDACs that corresponded to the Class I and Class II HDAC enzymes present in the blowfly, namely HDAC1 and 3 (Class I) and HDAC4 and 6 (Class II). The published data on the inhibition of human HDAC11 (corresponding to the other HDAC present in the blowfly) was not extensive enough with respect to the HDACi examined in the present study (see Supplementary Table 1) to allow for a separate analysis of this Class IV HDAC. The relationship between the blowfly bioassay data for each HDACi and the reported enzyme inhibition IC₅₀ values against the Class I and II human HDAC enzymes are shown in Fig. 5. The two parameters were significantly correlated for the Class I enzymes, but not for the Class II enzymes. However, even though a significant correlation existed for Class I enzymes across the whole data set, a number of compounds that were potent inhibitors of the human Class I enzymes showed no insecticidal activity (IC₅₀ > 1000 μ g/assay). Similarly, some potent human Class II HDAC inhibitors showed no insecticidal activity.

Table 2

Effects of HDACi and commercial insecticides on the development of blowfly larvae.

Drug group	Compound	Blowfly bioassay			
		Weight gain in first 24 h		Pupation	
		IC ₅₀	95% CI	IC ₅₀	95% CI
		(µg/assay)		(µg/assay)	
1) HDAC inhibitors					
Hydroxamic acids	Trichostatin	10.4	5.3-20.4	20.6	16.0-26.6
	CUDC-907	12.2	6.1-24.5	13.8	7.5-25.5
	AL1179-3b	13.9	7.3-26.2	20.0	14.6-27.3
	AR-42	34.0	26.9-43.7	28.0	20.1-38.3
	Quisinostat	100	39–260	274	149-501
	PG50	101	26-388	>200	
	Nexturostat	137	68-279	>1000	
	AL1179-84	254	79-816	918	619-1360
	Panobinostat	295	162-539	393	173-895
	Pracinostat	302	110-834	>1000	
	SBHA	356	215-588	550	405-747
	AL-1179-85	380	90-1607	863	746-1000
	SAHA	434	247-763	>1000	
	Givinostat	477	157-1444	>1000	
	M344	490	294-804	890	632-1257
	Resminostat	556	258-1200	>1000	
	Belinostat	740	426-1294	>1000	
	Naphthohydro. acid	778	335-1810	>1000	
	Droxinostat	>1000		>1000	
	CAY10603	>1000		>1000	
	VAHA	>1000		>1000	
	MC-1568	>1000		>1000	
		>1000		>1000	
	NVV38	>1000		>1000	
		>1000		>1000	
	BRD73054	>1000		>1000	
	CUDC-101	>1000		>1000	
	Rocilinostat	>1000		>1000	
	Tubastatin A	>1000		>1000	
	PCI-34051	>1000		>1000	
Cyclic depsipeptide	Romidensin	0 124	0 103-0 149	0 196	0 102-0 374
Benzamides	Entinostat	680	475-974	640	200-2056
Denbannaeb	Mocetinostat	>1000		>1000	200 2000
Thioester	KD5170	40.6	20.6-79.9	75.3	52.6-107.9
Disulfide	Psammaplin A	56.3	22.9-138.3	93.4	55.1-158.1
Thiolate	TCS HDAC620b	284	171-470	>1000	
Cyclic tetrapeptide	Apicidin	83.3	51.5-134.5	489	218-1097
Fatty acids	Valproic acid	>1000		>1000	
	AN-9	>1000		>1000	
Sesquiterpene lactone	Parthenolide	>1000		>1000	
2) Commercial blowfly insecticides					
Pyrimidine	Dicyclanil	0.115	0.0160-0.829	0.0634	0.0519-0.0776
Diamino-triazine	Cyromazine	1.27	0.673-2.40	1.54	0.600-3.96
Benzoyl phenyl urea	Diflubenzuron	0.230	0.133-0.400	0.119	0.0941-0.151

4. Discussion

The present study has examined the ability of a number of known HDACi to inhibit the growth and development of blowfly larvae, and correlated this effect with their ability to inhibit the HDAC activity of nuclear extracts prepared from blowfly eggs. There was a significant correlation, suggesting that their insecticidal activity was likely due to the inhibition of blowfly HDAC enzymes. Romidepsin was a very potent inhibitor of both blowfly larval growth and blowfly HDAC activity, the potency being equivalent to or greater than commercial blowfly insecticides. In addition, we have shown that a number of other HDACi have significant insecticidal activity against blowfly larvae, including hydroxamic acids (Trichostatin, CUDC-907, AL1179-3b, AR-42), a thioester (KD5170), a disulphide (Psammaplin A) and a cyclic tetrapeptide with a zinc-binding ketone (Apicidin).

While these HDACi validate the concept of a potentially valuable new target for insecticides, we are not advocating the use of the particular compounds reported herein as commercial insecticides. They would be too expensive to be economically viable for any livestock or agronomic production setting. Moreover, most of the more potent HDACi described are also potent inhibitors of human HDACi (IC₅₀ nM - μ M) and might prove cytotoxic in sheep and unacceptable in terms of human consumption of sheepmeat. Hence, while our demonstration of the potent insecticidal activity of a number of HDACi helps to prove the concept that HDACi may be effective insecticides, issues associated with cost of production and target pest selectivity need to be solved next.

Romidepsin is a prodrug that is first activated by reduction of its disulfide to the free thiol that can then bind to the catalytic Zn^{2+} in HDAC enzymes. Thiols or thiolates have a much lower binding affinity for Zn^{2+} than hydroxamic acids. The higher potency of romidepsin involves either a highly complementary fit of the conformationally constrained cyclic depsipeptide component of romidepsin with the enzyme, or higher metabolic stability than the hydroxamates. Apicidin is another compound with significant



Fig. 1. Effects of HDACi (coloured solid symbols and lines; named in key) and commercial insecticides (open symbols dashed lines; cyromazine \Diamond , diflubenzuron \Box , dicyclanil \bigcirc) on the growth of blowfly larvae. Each data point represents mean \pm SE, n = 2 assays at each compound concentration. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

insecticidal activity (Table 2) which also has a rigid cyclic tetrapeptide component that adds affinity to the relatively weak interaction between its ketone component and zinc. Interestingly, Engel et al. (2015) found that romidepsin inhibited the growth of asexual stage *Plasmodium falciparum* (IC₅₀ 0.1 μ M), the bloodstream form *Trypanosoma brucei* parasites (IC₅₀ 0.035 μ M), and was a potent inhibitor of HDAC enzyme activity in *P. falciparum* nuclear extracts (IC₅₀ 0.9 nM).

In contrast, most hydroxamic acid based inhibitors derive their affinity from zinc chelation which sometimes compensates for a suboptimal fit between the remaining features of the inhibitor and the enzyme active site. The 31 hydroxamic acids examined here have considerable structural diversity and are mostly potent inhibitors of human HDACs. They show quite a range of inhibitory potencies against blowfly larval growth over two log units (Table 2). Most of the hydroxamate-based inhibitors were derived from 4aminopyrimidine or 4-aminobenzene hydroxamic acids, which confer an extended linear shape to the fragment projecting towards Zn²⁺ in the enzyme. Trichostatin has a similarly rigid linear structure due to its highly conjugated olefin components. Other active inhibitors with a linear structure due to an aromatic group in conjugation with a double bond and hydroxamate are the cinnamic acid hydroxamates, panobinostat & pracinostat. The potent suberoylhydroxamates (AL1179-3b & PG50) have a more flexible linear zinc-binding extension like the similarly flexible but simpler parent compound SAHA, but exhibit superior activity attributed to their branched capping group that likely makes multiple interactions with the enzyme. PG50 was developed as a selective inhibitor of human HDAC6 (Gupta et al., 2010), however it seems to be a class I HDACi in the blowfly possibly suggesting its capping groups are too small to influence selectivity as the other hydroxamate inhibitors known to specifically inhibit human HDAC6 (tubacin & tubastatin A) were inactive in the blowfly bioassay. The reasons why other hydroxamates were inactive is not clear, but they do show how selectivity between highly homologous enzymes can be achieved, in this case away from blowfly and towards human. In principle this trend might be reversed with new compounds. Clues derived from the capping cyclic peptide groups away from the zinc-binding moieties of romidepsin and apicidin may steer the development of new compounds with greater potency and selectivity for the target enzyme to make better and safer insecticides.

Two aspects of the time course of insecticidal effects are important for blowfly control. Firstly, effective insecticides must kill, or inhibit the growth of early stage larvae before they can damage the host. Secondly, where the initial effects are inhibitory rather than lethal, they must persist over at least several days and then kill the larva to prevent it recovering and developing to damage the host. A comparison of the two bioassay IC₅₀ values is informative with respect to these time course considerations. The commercial insecticides show a pupation IC₅₀ that is similar (within two fold) to the 24 h weight gain IC₅₀, consistent with the larvae not recovering from an initial growth inhibition phase. This was also observed for seven of the eight HDACi highlighted in Fig. 2. Apicidin on the other hand showed a pupation IC₅₀ value almost 6fold greater than the weight gain IC₅₀, indicating some recovery of larvae after the initial inhibitory effects on growth.

A number of compounds showed potent inhibition of the nuclear extract HDAC activity, but only low or no activity in the larval bioassay (for example: nuclear enzyme assay CAY10603 IC₅₀ 0.165 μ M, CUDC-101 0.0317 μ M vs larval bioassay IC₅₀ > 1000 μ g/assay). This is likely due to poor uptake or low stability of the compounds in the larval assay. There are likely to be differences between the various compounds examined in terms of uptake across the larval cuticle (trans-cuticular uptake) and across the intestinal membranes (following ingestion), as well as access to the cellular target following uptake. Some of the compounds are likely to be metabolised to a greater degree than others by the blowfly xenobiotic-detoxification systems, which include esterases (Campbell et al., 1997), cytochromes P450 (Kotze, 1993) and glutathione transferases (Kotze and Rose, 1987).

Potency against human class I HDAC enzymes generally correlated with insecticidal activity, but some potent inhibitors of human Class I HDAC (IC₅₀ < 0.10 μ M) showed no insecticidal activity. This may be due to factors associated with uptake and stability of the compounds in the bioassay, as well as differences in the intrinsic level of interaction of the compounds with the human enzymes compared to the equivalent blowfly HDAC enzymes. Kotze et al. (2015) described some differences in the amino acid residues between the human and blowfly Class I HDACs, with catalytic domain amino acids showing 86% and 73% identities between human and blowfly HDAC1 and 3, respectively. The relationship between inhibitory effects of HDACi on human Class II HDACs and their insecticidal activity was poor, with no significant correlation between the two parameters. The catalytic domain amino acids differ to a much greater extent between the human Class II HDACs and their blowfly equivalents compared to the Class I comparisons, with % identities of 61%, 47% and 50% for HDAC 4 and the two catalytic domains of HDAC6, respectively, between the human and blowfly (Kotze et al., 2015). Hence, HDACi of human and blowfly Class II enzymes may show a lower level of relatedness than among inhibitors of Class I enzymes from the two species. The lack of correlation for Class II HDACs may be favourable for potential identification of more insect-specific HDACi that interact specifically with the blowfly Class II enzymes, while showing less inhibition of the human Class II enzymes. However, more information on the different roles played by the blowfly Class I and II HDAC enzymes is required before a preferred target HDAC Class or individual enzyme can be determined. Foglietti et al. (2006) found that RNAi -mediated silencing of Drosophila HDACs 1 and 3 resulted in inhibitory effects on growth curves for Drosophila Schneider (S2) cell lines, whereas silencing of HDACs 4, 6 and 11 did not inhibit cell growth, suggesting more important roles for the two Class I enzymes in cell viability. Du et al. (2010) reported that Drosophila HDAC6 loss-of-function mutant flies were viable and fertile,



NΗ

Н

Romidepsin

O

Disulfide:

HO

Br

HO



Fig. 2. Structures of HDACi with the most potent inhibition of blowfly larval development (larval weight gain $IC_{50} < 100 \mu g/assay$).

Psammaplin A

 Table 3
 Effects of HDACi on HDAC activity of nuclear extracts from blowfly eggs.

Drug group	Drug group Compound Nuclear extr		act assay	
		IC ₅₀ (μΜ)	95% CI	
Hydroxamic acids	Trichostatin	0.016	0.011-0.022	
5	CUDC-907	0.11	0.08-0.17	
	AR-42	0.21	0.18-0.26	
	Quisinostat	0.009	0.003-0.022	
	Nexturostat	5.1	3.2-8.3	
	Panobinostat	0.017	0.012-0.025	
	Pracinostat	0.69	0.58-0.82	
	SBHA	9.9	6.5-15.2	
	SAHA	0.39	0.30-0.50	
	Givinostat	0.19	0.15-0.24	
	M344	0.58	0.41-0.81	
	Resminostat	1.71	1.27-2.30	
	Belinostat	0.27	0.19-0.36	
	Naphthohydro. acid	83	54-128	
	Droxinostat	49	40-59	
	CAY10603	0.17	0.10-0.27	
	VAHA	>100		
	ABHA	2.6	1.5-4.6	
	Tubacin	26	18-37	
	HPOB	17	13-20	
	BRD73954	>100		
	CUDC-101	0.032	0.014-0.070	
	Rocilinostat	2.0	1.6-2.4	
	Tubastatin A	71	37-133	
	PCI-34051	>100		
Cyclic depsipeptide	Romidepsin	0.000014	0.00001-0.00002	
Benzamides	Entinostat	15	5-46	
	Mocetinostat	>100		
Thioester	KD5170	0.41	0.32-0.50	
Disulfide	Psammaplin A	0.015	0.007-0.032	
Thiolate	TCS HDAC620b	>100		
Cyclic tetrapeptide	Apicidin	0.72	0.45-1.14	
Fatty acid	Valproic acid	>100		
Sesquiterpene lactone	Parthenolide	>100		



Fig. 3. Effects of HDACi (named in key) on HDAC activity of nuclear extracts prepared from blowfly eggs. Each data point represents mean \pm SE, n=2 assays at each compound concentration.

suggesting that this enzyme may not be essential for the development of this fly species.

In conclusion, the present study shows that HDACi from various chemical groups can substantially inhibit the development of



Fig. 4. Relationship for HDACi in inhibiting blowfly larval development (larval weight gain IC_{50}) versus blowfly HDAC activity (nuclear extract IC_{50}). A: whole data set (n = 34), with Spearman correlation coefficient and *P* value; data points at 100 μ M for nuclear extract inhibition and/or 1000 μ g/assay for larval weight were measured as > 100 and > 1000, respectively. B: Only the most potent inhibitors of HDAC activity ($IC_{50} < 2.0 \ \mu$ M, n = 16), with Spearman correlation coefficient and *P* value; circled data points are for romidepsin, TSA, CUDC-907, AR 42, KD5170 and Psammaplin A.

blowfly larvae. In particular, romidepsin was at least equipotent with the major commercial blowfly insecticides, supporting the concept of inhibiting blowfly HDAC enzymes to produce new insecticides for preventing infection by sheep blowfly, and to potentially control other insects. There is a great deal of interest currently in developing HDAC inhibitors for use in chemotherapy against other human parasitic disease - malaria, toxoplasmosis, trypanosmiasis, schistosomiasis and leishmaniasis (Andrews et al., 2012a,b, 2014; Kelly et al., 2012; Hansen et al., 2014; Engel et al., 2015; Marek et al., 2015). A focus of these studies is the identification of HDACi that show selectivity for the parasite HDAC enzymes over the human enzymes. Similarly, further work on developing HDAC inhibitors as potent insecticides could focus on identifying insect-specific inhibitors, but at the very least should focus on producing HDACi that are cheap to manufacture and market as prospective insecticides.



Fig. 5. Relationship for HDACi in inhibiting larval development (larval weight gain IC_{50}) versus human Class I enzymes (HDAC1 \bigcirc , HDAC3 \blacksquare) (A) (n = 45), and human Class II enzymes (HDAC4 \bullet , and HDAC6 Δ) (B) (n = 37). Spearman correlation coefficients and *P* values shown. Data points at 20 μ M for human enzyme inhibition and/ or 1000 μ g/assay for larval weight were measured as > 20 and > 1000, respectively.

Acknowledgements:

Funding for this work was provided by Australian Wool Innovation Limited (ON-00110), and by the L.W. Bett Bequest. DF acknowledges the National Health and Medical Research Council for a Senior Principal Research Fellowship (1027369) and grants (1093378, 1074016) for developing antiparasitic HDAC inhibitors. The authors have no conflicts of interest concerning the work reported in this paper.

Appendix A. Supplementary data

Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.ijpddr.2017.01.001.

References

- Andrews, K.T., Walduck, A., Kelso, M.J., Fairlie, D.P., Saul, A., Parsons, P.G., 2000. Antimalarial effect of histone deacetylation inhibitors and mammalian tumour cytodifferentiating agents. Int. J. Parasitol. 30, 761–768.
- Andrews, K.T., Haque, A., Jones, M.K., 2012a. HDAC inhibitors in parasitic diseases. Immunol. Cell Biol. 90, 66–77.
- Andrews, K.T., Tran, T.N., Fairlie, D.P., 2012b. Towards histone deacetylase inhibitors as new antimalarial drugs. Curr. Pharm. Des. 18, 3467–3479.
- Andrews, K.T., Fisher, G., Skinner-Adams, T.S., 2014. Drug repurposing and human parasitic protozoan diseases. Int. J. Parasitol. Drugs Drug. Resist 4, 95–111.
- Arts, J., King, P., Mariën, A., Floren, W., Beliën, A., Janssen, L., Pilatte, I., Roux, B., Decrane, L., Gilissen, R., Hickson, I., Vreys, V., Cox, E., Bol, K., Talloen, W., Goris, I., Andries, L., Du Jardin, M., Janicot, M., Page, M., van Emelen, K., Angibaud, P., 2009. JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. Clin. Cancer Res. 15, 6841–6851.
- Atadja, P., 2009. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett. 280, 233–241.
- Balasubramanian, S., Ramos, J., Luo, W., Sirisawad, M., Verner, E., Buggy, J.J., 2008. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia 22, 1026–1034.
- Barbarotta, L., Hurley, K., 2015. Romidepsin for the treatment of peripheral T-cell lymphoma. J. Adv. Pract. Oncol. 6, 22–36.
- Baud, M.G., Leiser, T., Haus, P., Samlal, S., Wong, A.C., Wood, R.J., Petrucci, V., Gunaratnam, M., Hughes, S.M., Buluwela, L., Turlais, F., Neidle, S., Meyer-Almes, F.J., White, A.J., Fuchter, M.J., 2012. Defining the mechanism of action and enzymatic selectivity of psammaplin A against its epigenetic targets. J. Med. Chem. 55, 1731–1750.
- Bergman, J.A., Woan, K., Perez-Villarroel, P., Villagra, A., Sotomayor, E.M., Kozikowski, A.P., 2012. Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth. J. Med. Chem. 55, 9891–9899.
- Bradford, M.M., 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248–254.
- Butler, K.V., Kalin, J., Brochier, C., Vistoli, G., Langley, B., Kozikowski, A.P., 2010. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J. Am. Chem. Soc. 132, 10842–10846.
- Cairns, B.R., 2001. Emerging roles for chromatin remodeling in cancer biology. Trends Cell. Biol. 11, S15–S21.
- Campbell, P.M., Trott, J.F., Claudianos, C., Smyth, K.A., Russell, R.J., Oakeshott, J.G., 1997. Biochemistry of esterases associated with organophosphate resistance in *Lucilia cuprina* with comparisons to putative orthologues in other Diptera. Biochem. Genet. 35, 17–40.
- Darkin-Rattray, S.J., Gurnett, A.M., Myers, R.W., Dulski, P.M., Crumley, T.M., Allocco, J.J., Cannova, C., Meinke, P.T., Colletti, S.L., Bednarek, M.A., Singh, S.B., Goetz, M.A., Dombrowski, A.W., Polishook, J.D., Schmatz, D.M., 1996. Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc. Natl. Acad.Sci. U. S. A. 93, 13143–13147.
- Du, G., Liu, X., Chen, X., Song, M., Yan, Y., Jiao, R., Wang, C.C., 2010. Drosophila histone deacetylase 6 protects dopaminergic neurons against {alpha}-synuclein toxicity by promoting inclusion formation. Mol. Biol. Cell. 21, 2128–2137.
- Engel, J.A., Jones, A.J., Avery, V.M., Sumanadasa, S.D., Ng, S.S., Fairlie, D.P., Adams, T.S., Andrews, K.T., 2015. Profiling the anti-protozoal activity of anti-cancer HDAC inhibitors against Plasmodium and Trypanosoma parasites. Int. J. Parasitol. Drugs Drug. Resist 5, 117–126.
- Fass, D.M., Shah, R., Ghosh, B., Hennig, K., Norton, S., Zhao, W.N., Reis, S.A., Klein, P.S., Mazitschek, R., Maglathlin, R.L., Lewis, T.A., Haggarty, S.J., 2010. Effect of inhibiting histone deacetylase with short-chain carboxylic acids and their hydroxamic acid analogs on vertebrate development and neuronal chromatin. ACS Med. Chem. Lett. 2, 39–42.
- Fitzsimons, H.L., Schwartz, S., Given, F.M., Scott, M.J., 2013. The histone deacetylase HDAC4 regulates long-term memory in Drosophila. PLoS One 8, e83903.
- Foglietti, C., Filocamo, G., Cundari, E., De Rinaldis, E., Lahm, A., Cortese, R., Steinkühler, C., 2006. Dissecting the biological functions of Drosophila histone deacetylases by RNA interference and transcriptional profiling. J. Biol. Chem. 281, 17968–17976.
- Fournel, M., Bonfils, C., Hou, Y., Yan, P.T., Trachy-Bourget, M.C., Kalita, A., Liu, J., Lu, A.H., Zhou, N.Z., Robert, M.F., Gillespie, J., Wang, J.J., Ste-Croix, H., Rahil, J., Lefebvre, S., Moradei, O., Delorme, D., Macleod, A.R., Besterman, J.M., Li, Z., 2008. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol. Cancer Ther. 7, 759–768.
- Furumai, R., Matsuyama, A., Kobashi, N., Lee, K.H., Nishiyama, M., Nakajima, H., Tanaka, A., Komatsu, Y., Nishino, N., Yoshida, M., Horinouchi, S., 2002. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 62, 4916–4921.
- Gopal, Y.N., Arora, T.S., Van Dyke, M.W., 2007. Parthenolide specifically depletes histone deacetylase 1 protein and induces cell death through ataxia telangiectasia mutated. Chem. Biol. 14, 813–823.
- Gupta, P.K., Reid, R.C., Liu, L., Lucke, A.J., Broomfield, S.A., Andrews, M.R., Sweet, M.J., Fairlie, D.P., 2010. Inhibitors selective for HDAC6 in enzymes and cells. Bioorg. Med. Chem. Lett. 20, 7067–7070.
- Hajjar, N.P., Casida, J.E., 1978. Insecticidal benzoylphenyl ureas: structure-activity

relationships as chitin synthesis inhibitors. Science 200, 1499–1500.

- Hansen, F.K., Sumanadasa, S.D., Stenzel, K., Duffy, S., Meister, S., Marek, L., Schmetter, R., Kuna, K., Hamacher, A., Mordmüller, B., Kassack, M.U., Winzeler, E.A., Avery, V.M., Andrews, K.T., Kurz, T., 2014. Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages. Eur. J. Med. Chem. 82, 204–213.
- Hassig, C.A., Symons, K.T., Guo, X., Nguyen, P.M., Annable, T., Wash, P.L., Payne, J.E., Jenkins, D.A., Bonnefous, C., Trotter, C., Wang, Y., Anzola, J.V., Milkova, E.L., Hoffman, T.Z., Dozier, S.J., Wiley, B.M., Saven, A., Malecha, J.W., Davis, R.L., Muhammad, J., Shiau, A.K., Noble, S.A., Rao, T.S., Smith, N.D., Hager, J.H., 2008. KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity *in vitro* and in vivo. Mol. Cancer Ther. 7, 1054–1065.
- Heltweg, B., Dequiedt, F., Marshall, B.L., Brauch, C., Yoshida, M., Nishino, N., Verdin, E., Jung, M., 2004. Subtype selective substrates for histone deacetylases. J. Med. Chem. 47, 5235–5243.
- Hu, E., Dul, E., Sung, C.M., Chen, Z., Kirkpatrick, R., Zhang, G.F., Johanson, K., Liu, R., Lago, A., Hofmann, G., Macarron, R., de los Frailes, M., Perez, P., Krawiec, J., Winkler, J., Jaye, M., 2003. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J. Pharmacol. Exp. Ther. 307, 720–728.
- Iwamoto, M., Friedman, E.J., Sandhu, P., Agrawal, N.G., Rubin, E.H., Wagner, J.A., 2013. Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor. Cancer Chemother. Pharmacol. 72, 493–508.
- Jones, P., Altamura, S., Chakravarty, P.K., Cecchetti, O., De Francesco, R., Gallinari, P., Ingenito, R., Meinke, P.T., Petrocchi, A., Rowley, M., Scarpelli, R., Serafini, S., Steinkühler, C., 2006. A series of novel, potent, and selective histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. 16, 5948–5952.
- Kahnberg, P., Lucke, A.J., Glenn, M.P., Boyle, G.M., Tyndall, J.D.A., Parsons, P.G., Fairlie, D.P., 2006. Design, synthesis, potency, and cytoselectivity of anticancer agents derived by parallel synthesis from α-aminosuberic acid. J. Med. Chem. 49, 7611–7622.
- Kelly, J.M., Taylor, M.C., Horn, D., Loza, E., Kalvinsh, I., Björkling, F., 2012. Inhibitors of human histone deacetylase with potent activity against the African trypanosome *Trypanosoma brucei*. Bioorg. Med. Chem. Lett. 22, 1886–1890.
- Kim, D.H., Shin, J., Kwon, H.J., 2007. Psammaplin A is a natural prodrug that inhibits class I histone deacetylase. Exp. Mol. Med. 39, 47–55.
- Kotze, A.C., Rose, H.A., 1987. Glutathione S-transferases in the Australian sheep blowfly, *Lucilia cuprina* (wiedemann). Pestic. Biochem. Physiol. 29, 77–86.
- Kotze, A.C., Reynolds, S.E., 1990. Mechanical properties of the cuticle of *Manduca* sexta larvae treated with cyromazine. Pestic. Biochem. Physiol. 38, 267–272.
- Kotze, A.C., 1993. Cytochrome P-450 monoxygenases in larvae of insecticidesusceptible and insecticide-resistant strains of the Australian sheep blowfly, *Lucilia cuprina*. Pestic. Biochem. Physiol. 46, 65–72.
- Kotze, A.C., Bagnall, N.H., Ruffell, A.P., Pearson, R., 2014. Cloning, recombinant expression and inhibitor profiles of dihydrofolate reductase from the Australian sheep blow fly, Lucilia cuprina. Med. Vet. Entomol. 28, 297–306.
- Kotze, A.C., Hines, B.M., Bagnall, N.H., Anstead, C.A., Gupta, P., Reid, R.C., Ruffell, A.P., Fairlie, D.P., 2015. Histone deacetylase enzymes as drug targets for the control of the sheep blowfly, *Lucilia cuprina*. Int. J. Parasitol. Drugs Drug Resist 5, 201–208.
- Kozikowski, A.P., Tapadar, S., Luchini, D.N., Kim, K.H., Billadeau, D.D., 2008. Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6. J. Med. Chem. 51, 4370–4373.
- Krennhrubec, K., Marshall, B.L., Hedglin, M., Verdin, E., Ulrich, S.M., 2007. Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. Bioorg. Med. Chem. Lett. 17, 2874–2878.
- Lai, C.J., Bao, R., Tao, X., Wang, J., Atoyan, R., Qu, H., Wang, D.G., Yin, L., Samson, M., Forrester, J., Zifcak, B., Xu, G.X., DellaRocca, S., Zhai, H.X., Cai, X., Munger, W.E., Keegan, M., Pepicelli, C.V., Qian, C., 2010. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res. 70, 3647–3656.
- Lane, J., Jubb, T., Shepherd, R., Webb-Ware, J., Fordyce, G., 2015. Priority List of Endemic Diseases for the Red Meat Industries. Final Report. B.AHE.0010, Meat and Livestock Australia, North Sydney.
- Lee, J.H., Mahendran, A., Yao, Y., Ngo, L., Venta-Perez, G., Choy, M.L., Kim, N., Ham, W.S., Breslow, R., Marks, P.A., 2013. Development of a histone deacetylase 6 inhibitor and its biological effects. Proc. Natl. Acad. Sci. U. S. A. 110, 15704–15709.
- Leoni, F., Fossati, G., Lewis, E.C., Lee, J.K., Porro, G., Pagani, P., Modena, D., Moras, M.L., Pozzi, P., Reznikov, L.L., Siegmund, B., Fantuzzi, G., Dinarello, C.A., Mascagni, P., 2005. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation *in vivo*. Mol. Med. 11, 1–15.
- Levot, G.W., 1995. Resistance and the control of sheep ectoparasites. Int. J. Parasitol. 25, 1355–1362.
- Levot, G.W., 2012. Cyromazine resistance detected in Australian sheep blowfly. Aust. Vet. J. 90, 433–437.
- Lu, Q., Wang, D.S., Chen, C.S., Hu, Y.D., Chen, C.S., 2005. Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J. Med. Chem. 48, 5530–5535.
- Mai, A., Massa, S., Pezzi, R., Simeoni, S., Rotili, D., Nebbioso, A., Scognamiglio, A., Altucci, L., Loidl, P., Brosch, G., 2005. Class II (IIa)-selective histone deacetylase

inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl) pyrrolyl hydroxyamides. J. Med. Chem. 48, 3344–3353.

- Mandl-Weber, S., Meinel, F.G., Jankowsky, R., Oduncu, F., Schmidmaier, R., Baumann, P., 2010. The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells. Br. J. Haematol. 149, 518–528.
- Marek, M., Oliveira, G., Pierce, R.J., Jung, M., Sippl, W., Romier, C., 2015. Drugging the schistosome zinc-dependent HDACs: current progress and future perspectives. Future Med. Chem. 7, 783–800.
- Novotny-Diermayr, V., Sangthongpitag, K., Hu, C.Y., Wu, X., Sausgruber, N., Yeo, P., Greicius, G., Pettersson, S., Liang, A.L., Loh, Y.K., Bonday, Z., Goh, K.C., Hentze, H., Hart, S., Wang, H., Ethirajulu, K., Wood, J.M., 2010. SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. Mol. Cancer Ther. 9, 642–652.
- Olson, D.E., Wagner, F.F., Kaya, T., Gale, J.P., Aidoud, N., Davoine, E.L., Lazzaro, F., Weïwer, M., Zhang, Y.L., Holson, E.B., 2013. Discovery of the first histone deacetylase 6/8 dual inhibitors. J. Med. Chem. 56, 4816–4820.
- Phiel, C.J., Zhang, F., Huang, E.Y., Guenther, M.G., Lazar, M.A., Klein, P.S., 2001. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276, 36734–36741.
- Pile, L.A., Lee, F.W., Wassarman, D.A., 2001. The histone deacetylase inhibitor trichostatin A influences the development of *Drosophila melanogaster*. Cell. Mol. Life Sci. 58, 1715–1718.
- Plumb, J.A., Finn, P.W., Williams, R.J., Bandara, M.J., Romero, M.R., Watkins, C.J., La Thangue, N.B., Brown, R., 2003. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol. Cancer Ther. 2, 721–728.
- Proshkina, E.N., Shaposhnikov, M.V., Sadritdinova, A.F., Kudryavtseva, A.V., Moskalev, A.A., 2015. Basic mechanisms of longevity: a case study of Drosophila pro-longevity genes. Ageing Res. Rev. 24, 218–231.
- Qian, C., Lai, C.J., Bao, R., Wang, D.G., Wang, J., Xu, G.X., Atoyan, R., Qu, H., Yin, L., Samson, M., Zifcak, B., Ma, A.W., DellaRocca, S., Borek, M., Zhai, H.X., Cai, X., Voi, M., 2012. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling. Clin. Cancer Res. 18, 4104–4113.
- Rabizadeh, E., Merkin, V., Belyaeva, I., Shaklai, M., Zimra, Y., 2007. Pivanex, a histone deacetylase inhibitor, induces changes in BCR-ABL expression and when combined with STI571, acts synergistically in a chronic myelocytic leukemia cell line. Leuk. Res. 3, 1115–1123.
- Rajkumar, S.V., Kumar, S., 2016. Multiple myeloma: diagnosis and treatment. Mayo Clin. Proc. 91, 101–119.
- Richon, V.M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R.A., Marks, P.A., 1998. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. i5 Proc. Natl. Acad. Sci. U. S. A. 3003–3007.
- Sandeman, R.M., Levot, G.W., Heath, A.C., James, P.J., Greeff, J.C., Scott, M.J., Batterham, P., Bowles, V.M., 2014. Control of the sheep blowfly in Australia and New Zealand—are we there yet? Int. J. Parasitol. 44, 879–891.
- Santo, L., Hideshima, T., Kung, A.L., Tseng, J.C., Tamang, D., Yang, M., Jarpe, M., van Duzer, J.H., Mazitschek, R., Ogier, W.C., Cirstea, D., Rodig, S., Eda, H., Scullen, T., Canavese, M., Bradner, J., Anderson, K.C., Jones, S.S., Raje, N., 2012. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 119, 2579–2589.
- Schwartz, S., Truglio, M., Scott, M.J., Fitzsimons, H.L., 2016. Long-term memory in Drosophila is influenced by histone deacetylase HDAC4 interacting with SUMOconjugating enzyme Ubc9. Genetics 203, 1249–1264.
- Sharma, S., Taliyan, R., 2015. Transcriptional dysregulation in Huntington's disease: the role of histone deacetylases. Pharmacol. Res. 100, 157–169.
- Suzuki, T., Kouketsu, A., Itoh, Y., Hisakawa, S., Maeda, S., Yoshida, M., Nakagawa, H., Miyata, N., 2006. Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate. J. Med. Chem. 49, 4809–4812.
- Tachibana, S.I., Numata, H., 2001. An artificial diet for blowfly larvae, *Lucilia sericata* (Meigen). Appl. Entomol. Zool. 36, 521–523.
- Tellam, R.L., Bowles, V.M., 1997. Control of blowfly strike in sheep: current strategies and future prospects. Int. J. Parasitol. 27, 261–273.
- Thompson, C.A., 2014. Belinostat approved for use in treating rare lymphoma. Am. J. Health Syst. Pharm. 71, 1328.
- Tseng, Y.C., Kulp, S.K., Lai, I.L., Hsu, E.C., He, W.A., Frankhouser, D.E., Yan, P.S., Mo, X., Bloomston, M., Lesinski, G.B., Marcucci, G., Guttridge, D.C., Bekaii-Saab, T., Chen, C.S., 2015. Preclinical investigation of the novel histone deacetylase inhibitor AR-42 in the treatment of cancer-induced cachexia. J. Natl. Cancer Inst. 107 djv274.
- Wheatley, N.C., Andrews, K.T., Tran, T.L., Lucke, A.J., Reid, R.C., Fairlie, D.P., 2010. Antimalarial histone deacetylase inhibitors containing cinnamate or NSAID components. Bioorg. Med. Chem. Lett. 20, 7080–7084.
- Wood, T.E., Dalili, S., Simpson, C.D., Sukhai, M.A., Hurren, R., Anyiwe, K., Mao, X., Suarez Saiz, F., Gronda, M., Eberhard, Y., MacLean, N., Ketela, T., Reed, J.C., Moffat, J., Minden, M.D., Batey, R.A., Schimmer, A.D., 2010. Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. Mol. Cancer Ther. 9, 246–256.
- Yoshida, M., Horinouchi, S., Beppu, T., 1995. Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays 17, 423–430.